|
NZ618298A
(en)
|
2001-11-13 |
2015-04-24 |
Univ Pennsylvania |
A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
|
|
JP4810062B2
(ja)
*
|
2001-12-17 |
2011-11-09 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
アデノ随伴ウイルス（ａａｖ）血清型８の配列
|
|
US9441244B2
(en)
|
2003-06-30 |
2016-09-13 |
The Regents Of The University Of California |
Mutant adeno-associated virus virions and methods of use thereof
|
|
US9233131B2
(en)
|
2003-06-30 |
2016-01-12 |
The Regents Of The University Of California |
Mutant adeno-associated virus virions and methods of use thereof
|
|
HUE035567T2
(en)
*
|
2003-09-30 |
2018-05-28 |
Univ Pennsylvania |
Adeno-associated virus (AAV) clusters, sequences, vectors and applications containing them
|
|
WO2006033672A2
(en)
|
2004-04-28 |
2006-03-30 |
The Trustees Of The University Of Pennsylvania |
Immunization regimen with e4-deleted adenovirus prime and e1-deleted adenovirus boost
|
|
WO2006078279A2
(en)
|
2004-04-28 |
2006-07-27 |
The Trustees Of The University Of Pennsylvania |
Sequential delivery of immunogenic molecules via adenovirus and adeno-associated virus-mediated administrations
|
|
EP1866422B1
(en)
|
2005-04-07 |
2016-04-06 |
The Trustees of The University of Pennsylvania |
Method of increasing the function of an aav vector
|
|
US7588772B2
(en)
|
2006-03-30 |
2009-09-15 |
Board Of Trustees Of The Leland Stamford Junior University |
AAV capsid library and AAV capsid proteins
|
|
CN101460055A
(zh)
*
|
2006-04-07 |
2009-06-17 |
得克萨斯大学体系董事会 |
和腺伴随病毒-噬菌体颗粒相关的方法和组合物
|
|
EP2016174A2
(en)
*
|
2006-04-28 |
2009-01-21 |
The Trustees of the University of Pennsylvania |
Modified aav vectors having reduced capsid immunogenicity and use thereof
|
|
EP2018421B1
(en)
|
2006-04-28 |
2012-12-19 |
The Trustees of the University of Pennsylvania |
Scalable production method for aav
|
|
HRP20161150T1
(hr)
|
2007-04-09 |
2016-11-18 |
University Of Florida Research Foundation, Inc. |
PRIPRAVCI rAAV VEKTORA KOJI IMAJU TIROZIN-MODIFICIRANE CAPSID PROTEINE I POSTUPCI ZA UPORABU
|
|
US9725485B2
(en)
*
|
2012-05-15 |
2017-08-08 |
University Of Florida Research Foundation, Inc. |
AAV vectors with high transduction efficiency and uses thereof for gene therapy
|
|
EP2019143A1
(en)
*
|
2007-07-23 |
2009-01-28 |
Genethon |
CNS gene delivery using peripheral administration of AAV vectors
|
|
EP2058401A1
(en)
*
|
2007-10-05 |
2009-05-13 |
Genethon |
Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
|
|
WO2009108274A2
(en)
*
|
2008-02-26 |
2009-09-03 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for adeno-associated virus (aav) with hi loop mutations
|
|
WO2009137006A2
(en)
|
2008-04-30 |
2009-11-12 |
The University Of North Carolina At Chapel Hill |
Directed evolution and in vivo panning of virus vectors
|
|
US9217155B2
(en)
|
2008-05-28 |
2015-12-22 |
University Of Massachusetts |
Isolation of novel AAV'S and uses thereof
|
|
US11219696B2
(en)
|
2008-12-19 |
2022-01-11 |
Nationwide Children's Hospital |
Delivery of polynucleotides using recombinant AAV9
|
|
ES2634118T3
(es)
|
2009-02-11 |
2017-09-26 |
The University Of North Carolina At Chapel Hill |
Vectores de virus modificados y métodos para fabricar y utilizar los mismos
|
|
US10920244B2
(en)
|
2009-04-30 |
2021-02-16 |
The Trustees Of The University Of Pennsylvania |
Compositions for targeting conducting airway cells comprising adeno-associated virus constructs
|
|
US8734809B2
(en)
|
2009-05-28 |
2014-05-27 |
University Of Massachusetts |
AAV's and uses thereof
|
|
WO2010141706A1
(en)
*
|
2009-06-03 |
2010-12-09 |
Cedars-Sinai Medical Center |
Effective vector platform for gene transfer and gene therapy
|
|
US20120244127A1
(en)
|
2009-10-01 |
2012-09-27 |
The Trustees Of The University Of Pennsylvania |
AAV Vectors Expressing SEC10 for Treating Kidney Damage
|
|
WO2011126808A2
(en)
|
2010-03-29 |
2011-10-13 |
The Trustees Of The University Of Pennsylvania |
Pharmacologically induced transgene ablation system
|
|
US9315825B2
(en)
|
2010-03-29 |
2016-04-19 |
The Trustees Of The University Of Pennsylvania |
Pharmacologically induced transgene ablation system
|
|
CA2833912C
(en)
|
2010-04-23 |
2021-09-21 |
University Of Massachusetts |
Aav-based treatment of cholesterol-related disorders
|
|
WO2011133874A1
(en)
|
2010-04-23 |
2011-10-27 |
University Of Massachusetts |
Multicistronic expression constructs
|
|
JP5963743B2
(ja)
|
2010-04-23 |
2016-08-03 |
ユニバーシティ オブ マサチューセッツ |
Ｃｎｓターゲティングａａｖベクターおよびその使用方法
|
|
US8663624B2
(en)
|
2010-10-06 |
2014-03-04 |
The Regents Of The University Of California |
Adeno-associated virus virions with variant capsid and methods of use thereof
|
|
JP5704361B2
(ja)
*
|
2010-10-27 |
2015-04-22 |
学校法人自治医科大学 |
神経系細胞への遺伝子導入のためのアデノ随伴ウイルスビリオン
|
|
US9409953B2
(en)
*
|
2011-02-10 |
2016-08-09 |
The University Of North Carolina At Chapel Hill |
Viral vectors with modified transduction profiles and methods of making and using the same
|
|
SG10201601110VA
(en)
|
2011-02-17 |
2016-03-30 |
Univ Pennsylvania |
Compositions and methods for altering tissue specificity and improving aav9-mediated gene transfer
|
|
EP2699688A1
(en)
|
2011-04-20 |
2014-02-26 |
The Trustees Of The University Of Pennsylvania |
Regimens and compositions for aav-mediated passive immunization of airborne pathogens
|
|
US9226976B2
(en)
|
2011-04-21 |
2016-01-05 |
University Of Massachusetts |
RAAV-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
|
|
MX349138B
(es)
|
2011-04-22 |
2017-07-13 |
Univ California |
Variones de virus adeno-asociados con capside variante y sus metodos de uso.
|
|
US20130039888A1
(en)
*
|
2011-06-08 |
2013-02-14 |
Nationwide Children's Hospital Inc. |
Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders
|
|
EP3147295B2
(en)
*
|
2011-08-24 |
2023-11-22 |
The Board of Trustees of the Leland Stanford Junior University |
New avv capsid proteins for nucleic acid transfer
|
|
EP2764119A2
(en)
|
2011-10-05 |
2014-08-13 |
Genelux Corporation |
Method for detecting replication or colonization of a biological therapeutic
|
|
US9226936B2
(en)
|
2011-10-28 |
2016-01-05 |
The Wistar of Anatomy and Biology |
Methods and compositions for enhancing the therapeutic effect of anti-tumor T cells
|
|
US10238755B2
(en)
|
2011-11-30 |
2019-03-26 |
The Wistar Institute Of Anatomy And Biology |
Methods and compositions for regulation of cell aging, carcinogenesis and reprogramming
|
|
EP2601968A1
(en)
*
|
2011-12-06 |
2013-06-12 |
Deutsches Krebsforschungszentrum |
HPV derived polynucleic acids for therapy
|
|
US9611305B2
(en)
|
2012-01-06 |
2017-04-04 |
Mayo Foundation For Medical Education And Research |
Treating cardiovascular or renal diseases
|
|
US20140087362A1
(en)
|
2012-03-16 |
2014-03-27 |
Aladar A. Szalay |
Methods for assessing effectiveness and monitoring oncolytic virus treatment
|
|
WO2013158265A1
(en)
|
2012-04-20 |
2013-10-24 |
Genelux Corporation |
Imaging methods for oncolytic virus therapy
|
|
WO2013170078A1
(en)
*
|
2012-05-09 |
2013-11-14 |
Oregon Health & Science University |
Adeno associated virus plasmids and vectors
|
|
US10294281B2
(en)
|
2012-05-15 |
2019-05-21 |
University Of Florida Research Foundation, Incorporated |
High-transduction-efficiency rAAV vectors, compositions, and methods of use
|
|
US12358954B2
(en)
|
2012-05-15 |
2025-07-15 |
University Of Florida Research Foundation, Incorporated |
Capsid-modified rAAV vector compositions and methods therefor
|
|
AU2013287281B2
(en)
|
2012-07-11 |
2018-04-26 |
The Trustees Of The University Of Pennsylvania |
AAV-mediated gene therapy for RPGR x-linked retinal degeneration
|
|
US20150252384A1
(en)
|
2012-08-01 |
2015-09-10 |
National Children's Hospital |
Intrathecal delivery of recombinant adeno-associated virus 9
|
|
EP2692868A1
(en)
|
2012-08-02 |
2014-02-05 |
Universitat Autònoma De Barcelona |
Adeno-associated viral (AAV) vectors useful for transducing adipose tissue
|
|
PL2900686T3
(pl)
*
|
2012-09-28 |
2021-01-25 |
The University Of North Carolina At Chapel Hill |
Wektory aav ukierunkowane na oligodendrocyty
|
|
US20140140959A1
(en)
|
2012-10-05 |
2014-05-22 |
Aladar A. Szalay |
Energy Absorbing-Based Diagnostic and Therapeutic Methods Employing Nucleic Acid Molecules Encoding Chromophore-Producing Enzymes
|
|
EP2749569A1
(en)
|
2012-12-28 |
2014-07-02 |
Annibale Alessandro Puca |
Variant of BPIFB4 protein
|
|
US8957044B2
(en)
|
2013-03-01 |
2015-02-17 |
Wake Forest University Health Sciences |
Systemic gene replacement therapy for treatment of X-linked myotubular myopathy (XLMTM)
|
|
AU2014244167A1
(en)
*
|
2013-03-13 |
2015-10-08 |
The Children's Hospital Of Philadelphia |
Adeno-associated virus vectors and methods of use thereof
|
|
WO2014159247A1
(en)
|
2013-03-14 |
2014-10-02 |
University Of Florida Research Foundation, Inc. |
Di-amino acid repeat-containing proteins associated with als
|
|
WO2014144229A1
(en)
*
|
2013-03-15 |
2014-09-18 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for dual glycan binding aav vectors
|
|
MX386059B
(es)
|
2013-03-15 |
2025-03-18 |
Univ Pennsylvania |
COMPOSICIONES Y SUS usos EN EL TRATAMIENTO DE LA MUCOPOLISACARIDOSIS TIPO I.
|
|
US9719106B2
(en)
|
2013-04-29 |
2017-08-01 |
The Trustees Of The University Of Pennsylvania |
Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
|
|
CA2907799A1
(en)
*
|
2013-05-31 |
2014-12-04 |
The Regents Of The University Of California |
Adeno-associated virus variants and methods of use thereof
|
|
EP3044318B1
(en)
|
2013-09-13 |
2019-05-01 |
California Institute of Technology |
Selective recovery
|
|
EP3049527A4
(en)
|
2013-09-26 |
2017-08-16 |
University of Florida Research Foundation, Inc. |
Synthetic combinatorial aav capsid library for targeted gene therapy
|
|
WO2015054258A1
(en)
*
|
2013-10-07 |
2015-04-16 |
Kiromic, Llc |
Compositions and methods for treating cardiovascular diseases using disease-specific promoter
|
|
EP3459965B1
(en)
*
|
2013-10-11 |
2020-12-02 |
Massachusetts Eye & Ear Infirmary |
Methods of predicting ancestral virus sequences and uses thereof
|
|
WO2015103438A2
(en)
|
2014-01-02 |
2015-07-09 |
Genelux Corporation |
Oncolytic virus adjunct therapy with agents that increase virus infectivity
|
|
GB201403684D0
(en)
*
|
2014-03-03 |
2014-04-16 |
King S College London |
Vector
|
|
US10072251B2
(en)
|
2014-02-19 |
2018-09-11 |
University Of Massachusetts |
Recombinant AAVS having useful transcytosis properties
|
|
MX377804B
(es)
|
2014-03-09 |
2025-03-11 |
Univ Pennsylvania |
Composiciones utiles en el tratamiento de deficiencia de la ornitina transcarbamilasa (otc).
|
|
PL3117005T3
(pl)
|
2014-03-10 |
2024-11-04 |
Uniqure Ip B.V. |
Dodatkowo ulepszone wektory aav produkowane w komórkach owadzich
|
|
KR102288849B1
(ko)
|
2014-03-17 |
2021-08-12 |
애드베룸 바이오테크놀로지스, 인코포레이티드 |
원추세포에서 증강된 유전자 발현을 위한 조성물 및 방법
|
|
US10280418B2
(en)
|
2014-03-18 |
2019-05-07 |
Univeristy Of Massachusetts |
RAAV-based compositions and methods for treating amyotrophic lateral sclerosis
|
|
EP2933335A1
(en)
|
2014-04-18 |
2015-10-21 |
Genethon |
A method of treating peripheral neuropathies and motor neuron diseases
|
|
EP3134115A4
(en)
|
2014-04-25 |
2017-10-25 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for treating metastatic breast cancer and other cancers in the brain
|
|
EP3134431B1
(en)
|
2014-04-25 |
2021-04-07 |
The Trustees Of The University Of Pennsylvania |
Ldlr variants and their use in compositions for reducing cholesterol levels
|
|
WO2015164786A1
(en)
|
2014-04-25 |
2015-10-29 |
University Of Massachusetts |
Recombinant aav vectors useful for reducing immunity against transgene products
|
|
HRP20201530T1
(hr)
|
2014-05-13 |
2020-12-11 |
The Trustees Of The University Of Pennsylvania |
Kompozicije koje sadrže aav koji eksprimira konstrukte dvojnih antitijela i njihove primjene
|
|
US10689653B2
(en)
|
2014-06-03 |
2020-06-23 |
University Of Massachusetts |
Compositions and methods for modulating dysferlin expression
|
|
US10577627B2
(en)
|
2014-06-09 |
2020-03-03 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
|
EP2960336A1
(en)
|
2014-06-27 |
2015-12-30 |
Genethon |
Efficient systemic treatment of dystrophic muscle pathologies
|
|
AU2015320694B2
(en)
|
2014-09-24 |
2021-11-11 |
City Of Hope |
Adeno-associated virus vector variants for high efficiency genome editing and methods thereof
|
|
WO2016054554A1
(en)
|
2014-10-03 |
2016-04-07 |
University Of Massachusetts |
Heterologous targeting peptide grafted aavs
|
|
JP6842410B2
(ja)
|
2014-10-03 |
2021-03-17 |
ユニバーシティ オブ マサチューセッツ |
新規の高効率ライブラリーにより同定されるａａｖベクター
|
|
EA201700181A1
(ru)
|
2014-10-14 |
2017-09-29 |
Галозим, Инк. |
Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования
|
|
WO2016065001A1
(en)
|
2014-10-21 |
2016-04-28 |
University Of Massachusetts |
Recombinant aav variants and uses thereof
|
|
AU2015342997B2
(en)
|
2014-11-05 |
2021-11-18 |
Research Institute At Nationwide Children's Hospital |
Methods and materials for producing recombinant viruses in eukaryotic microalgae
|
|
WO2016073693A2
(en)
|
2014-11-05 |
2016-05-12 |
Voyager Therapeutics, Inc. |
Aadc polynucleotides for the treatment of parkinson's disease
|
|
CN114717264A
(zh)
|
2014-11-14 |
2022-07-08 |
沃雅戈治疗公司 |
治疗肌萎缩性侧索硬化(als)的组合物和方法
|
|
CA2975583A1
(en)
|
2014-11-14 |
2016-05-19 |
Voyager Therapeutics, Inc. |
Modulatory polynucleotides
|
|
CA2967393A1
(en)
*
|
2014-11-21 |
2016-05-26 |
The University Of North Carolina At Chapel Hill |
Aav vectors targeted to the central nervous system
|
|
US11697825B2
(en)
|
2014-12-12 |
2023-07-11 |
Voyager Therapeutics, Inc. |
Compositions and methods for the production of scAAV
|
|
JP6754361B2
(ja)
|
2014-12-16 |
2020-09-09 |
ボード オブ リージェンツ オブ ザ ユニバーシティ オブ ネブラスカ |
若年型バッテン病のための遺伝子療法
|
|
EP3978614A3
(en)
|
2015-01-07 |
2022-07-27 |
Universitat Autònoma de Barcelona |
Single-vector gene construct comprising insulin and glucokinase genes
|
|
EP4599851A2
(en)
|
2015-01-16 |
2025-08-13 |
University of Washington |
Novel micro-dystrophins and related methods of use
|
|
US20180030096A1
(en)
|
2015-02-03 |
2018-02-01 |
University Of Florida Research Foundation, Inc. |
Recombinant aav1, aav5, and aav6 capsid mutants and uses thereof
|
|
JP6929791B2
(ja)
|
2015-02-09 |
2021-09-01 |
デューク ユニバーシティ |
エピゲノム編集のための組成物および方法
|
|
EP3256170B1
(en)
|
2015-02-13 |
2020-09-23 |
University of Massachusetts |
Compositions and methods for transient delivery of nucleases
|
|
JP7095994B2
(ja)
|
2015-03-02 |
2022-07-05 |
アドヴェラム バイオテクノロジーズ， インコーポレイテッド |
ポリヌクレオチドを網膜錐体に硝子体内送達するための組成物及び方法
|
|
AU2016229000B2
(en)
|
2015-03-10 |
2021-11-04 |
The Trustees Of Columbia University In The City Of New York |
Recombinant Glut1 adeno-associated viral vector constructs and related methods for restoring Glut1 expression
|
|
CA2979065A1
(en)
|
2015-03-24 |
2016-09-29 |
The Regents Of The University Of California |
Adeno-associated virus variants and methods of use thereof
|
|
WO2016172008A1
(en)
|
2015-04-24 |
2016-10-27 |
University Of Massachusetts |
Modified aav constructions and uses thereof
|
|
US20180110877A1
(en)
|
2015-04-27 |
2018-04-26 |
The Trustees Of The University Of Pennsylvania |
DUAL AAV VECTOR SYSTEM FOR CRISPR/Cas9 MEDIATED CORRECTION OF HUMAN DISEASE
|
|
AU2016256894B2
(en)
|
2015-05-07 |
2020-11-26 |
Massachusetts Eye And Ear Infirmary |
Methods of delivering an agent to the eye
|
|
GB201508026D0
(en)
|
2015-05-11 |
2015-06-24 |
Ucl Business Plc |
Capsid
|
|
CA2985786A1
(en)
|
2015-05-12 |
2016-11-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Aav isolate and fusion protein comprising nerve growth factor signal peptide and parathyroid hormone
|
|
US11535665B2
(en)
|
2015-05-13 |
2022-12-27 |
The Trustees Of The University Of Pennsylvania |
AAV-mediated expression of anti-influenza antibodies and methods of use thereof
|
|
US20170067028A1
(en)
*
|
2015-05-15 |
2017-03-09 |
Douglas J. Ballon |
Radiolabeling of adeno associated virus
|
|
US10509045B2
(en)
|
2015-05-29 |
2019-12-17 |
University Of Florida Research Foundation, Incorporated |
Methods for diagnosing Huntington's disease
|
|
ES3009026T3
(en)
|
2015-07-22 |
2025-03-25 |
Univ Duke |
High-throughput screening of regulatory element function with epigenome editing technologies
|
|
JP7166168B2
(ja)
*
|
2015-07-30 |
2022-11-07 |
マサチューセッツ アイ アンド イヤー インファーマリー |
祖先ウイルス配列およびその使用
|
|
WO2017023801A1
(en)
|
2015-07-31 |
2017-02-09 |
Regents Of The University Of Minnesota |
Intracellular genomic transplant and methods of therapy
|
|
KR102745604B1
(ko)
|
2015-08-06 |
2024-12-23 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
Glp-1 및 대사성 질환 치료용 조성물에서 이의 용도
|
|
JP6905755B2
(ja)
|
2015-08-25 |
2021-07-21 |
デューク ユニバーシティ |
Ｒｎａガイド型エンドヌクレアーゼを使用してゲノム工学における特異性を改善する組成物および方法
|
|
KR20180057636A
(ko)
|
2015-08-31 |
2018-05-30 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
반려 동물 치료용 aav-epo
|
|
JP7261583B2
(ja)
|
2015-09-24 |
2023-04-20 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
補体媒介性疾患を処置するための組成物及び方法
|
|
CA2996420A1
(en)
|
2015-09-28 |
2017-04-06 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for antibody-evading virus vectors
|
|
WO2017062750A1
(en)
|
2015-10-09 |
2017-04-13 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods useful in treating stargardt's disease and other ocular disorders
|
|
EP4089175A1
(en)
|
2015-10-13 |
2022-11-16 |
Duke University |
Genome engineering with type i crispr systems in eukaryotic cells
|
|
WO2017066764A2
(en)
*
|
2015-10-16 |
2017-04-20 |
William Marsh Rice University |
Modification of n-terminal region of capsid proteins for enhanced properties of adeno-associated viruses
|
|
DK3364997T5
(da)
|
2015-10-22 |
2024-09-30 |
Univ Massachusetts |
Aspartoacylase genterapi til behandling af canavans sygdom
|
|
EP3364996B1
(en)
*
|
2015-10-22 |
2021-08-25 |
University of Massachusetts |
Prostate-targeting adeno-associated virus serotype vectors
|
|
US12188037B2
(en)
|
2015-10-22 |
2025-01-07 |
University Of Florida Research Foundation, Incorporated |
Synthetic combinatorial AAV3 capsid library
|
|
WO2017070491A1
(en)
*
|
2015-10-23 |
2017-04-27 |
Applied Genetic Technologies Corporation |
Ophthalmic formulations
|
|
US20180230489A1
(en)
|
2015-10-28 |
2018-08-16 |
Voyager Therapeutics, Inc. |
Regulatable expression using adeno-associated virus (aav)
|
|
WO2017075119A1
(en)
|
2015-10-28 |
2017-05-04 |
The Trustees Of The Univeresity Of Pennsylvania |
Intrathecal administration of adeno-associated-viral vectors for gene therapy
|
|
SG10201912763QA
(en)
|
2015-11-05 |
2020-02-27 |
Bamboo Therapeutics Inc |
Modified friedreich ataxia genes and vectors for gene therapy
|
|
CA3006569A1
(en)
|
2015-12-02 |
2017-06-08 |
Voyager Therapeutics, Inc. |
Assays for the detection of aav neutralizing antibodies
|
|
FR3044926B1
(fr)
|
2015-12-09 |
2020-01-31 |
Genethon |
Outils de therapie genique efficaces pour le saut de l'exon 53 de la dystrophine
|
|
IL259850B2
(en)
|
2015-12-11 |
2023-11-01 |
Univ Pennsylvania |
Gene therapy for treating familial hypercholesterolemia
|
|
CA3007476A1
(en)
|
2015-12-11 |
2017-06-15 |
Massachusetts Eye And Ear Infirmary |
Materials and methods for delivering nucleic acids to cochlear and vestibular cells
|
|
EP3387138B1
(en)
|
2015-12-11 |
2022-01-26 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav9
|
|
CA3007495C
(en)
|
2015-12-11 |
2023-04-11 |
California Institute Of Technology |
Targeting peptides for directing adeno-associated viruses (aavs)
|
|
EP3387118B1
(en)
|
2015-12-11 |
2022-04-06 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aavrh10
|
|
EP3387117B1
(en)
|
2015-12-11 |
2022-11-23 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav8
|
|
WO2017100674A1
(en)
|
2015-12-11 |
2017-06-15 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav1
|
|
CN109072254A
(zh)
*
|
2015-12-14 |
2018-12-21 |
宾夕法尼亚州大学信托人 |
用于治疗脊髓性肌萎缩的腺相关病毒载体
|
|
WO2017106345A1
(en)
|
2015-12-14 |
2017-06-22 |
The Trustees Of The University Of Pennsylvania |
Composition for treatment of crigler-najjar syndrome
|
|
ES2826384T3
(es)
|
2015-12-14 |
2021-05-18 |
Univ Pennsylvania |
Terapia génica para trastornos oculares
|
|
EP3411059A4
(en)
|
2016-02-02 |
2019-10-16 |
University Of Massachusetts |
METHOD FOR INCREASING THE EFFECTIVENESS OF THE SYSTEMIC DELIVERY OF AVV GENES TO THE CENTRAL NERVOUS SYSTEM
|
|
IL260959B2
(en)
|
2016-02-03 |
2024-09-01 |
Univ Pennsylvania |
Gene therapy for treating mucopolysaccharidosis type i
|
|
WO2017136202A1
(en)
|
2016-02-05 |
2017-08-10 |
Emory University |
Injection of single-stranded or self-complementary adeno-associated virus 9 into the cerebrospinal fluid
|
|
US11060088B2
(en)
|
2016-02-12 |
2021-07-13 |
University Of Massachusetts |
Anti-angiogenic miRNA therapeutics for inhibiting corneal neovascularization
|
|
CA3019847A1
(en)
|
2016-04-04 |
2017-10-12 |
University Of Florida Research Foundation, Incorporated |
Manipulation of eif3 to modulate repeat associated non-atg (ran) translation
|
|
EP3440210A4
(en)
|
2016-04-05 |
2019-11-27 |
University of Massachusetts |
COMPOSITIONS AND METHOD FOR SELECTIVELY INHIBITING THE EXPRESSION OF GRAINYHEAD LIKE PROTEIN
|
|
EP3443001B1
(en)
|
2016-04-11 |
2025-04-30 |
Obsidian Therapeutics, Inc. |
REGULATED BIOCIRCUIT SYSTEMS
|
|
EP3443081A4
(en)
|
2016-04-13 |
2019-10-30 |
Duke University |
CRISPR / CAS9-BASED REPRESSORS FOR IN VIVO SHUT-OFF OF GEN-TARGETS AND METHOD OF USE
|
|
US11413356B2
(en)
|
2016-04-15 |
2022-08-16 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance
|
|
KR102824067B1
(ko)
|
2016-04-15 |
2025-06-23 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Icos 리간드 변이체 면역조절 단백질 및 그의 용도
|
|
MA43552A
(fr)
|
2016-04-15 |
2018-11-07 |
Alpine Immune Sciences Inc |
Protéines immunomodulatrices à variants de cd80 et leurs utilisations
|
|
CN109661470A
(zh)
|
2016-04-15 |
2019-04-19 |
宾夕法尼亚州大学信托人 |
新型aav8突变衣壳和含有其的组合物
|
|
SG11201808176TA
(en)
|
2016-04-15 |
2018-10-30 |
The Trustees Of The Univ Of Pennsyvania |
Gene therapy for treating mucopolysaccharidosis type ii
|
|
BR112018071200A2
(pt)
|
2016-04-15 |
2019-04-09 |
The Trustees Of The University Of Pennsylvania |
terapia genética para o tratamento da hemofilia a
|
|
US11197937B2
(en)
|
2016-04-15 |
2021-12-14 |
The Trustees Of The University Of Pennsylvania |
Compositions for treatment of wet age-related macular degeneration
|
|
US11401527B2
(en)
|
2016-04-17 |
2022-08-02 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods useful for prophylaxis of organophosphates
|
|
EP3448874A4
(en)
|
2016-04-29 |
2020-04-22 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
US11299751B2
(en)
|
2016-04-29 |
2022-04-12 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
|
EP3452495B1
(en)
*
|
2016-05-03 |
2021-06-23 |
Children's Medical Research Institute |
Adeno-associated virus polynucleotides, polypeptides and virions
|
|
RU2725286C2
(ru)
|
2016-05-13 |
2020-06-30 |
4Д Молекьюлар Терапьютикс Инк. |
Варианты капсидов аденоассоциированного вируса и способы их применения
|
|
IL262784B2
(en)
|
2016-05-18 |
2023-10-01 |
Voyager Therapeutics Inc |
modulatory polynucleotides
|
|
SG11201809643UA
(en)
|
2016-05-18 |
2018-12-28 |
Voyager Therapeutics Inc |
Compositions and methods of treating huntington's disease
|
|
JP2019517274A
(ja)
|
2016-06-13 |
2019-06-24 |
ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｎｏｒｔｈ Ｃａｒｏｌｉｎａ Ａｔ Ｃｈａｐｅｌ Ｈｉｌｌ |
最適化されたｃｌｎ１遺伝子および発現カセットおよびそれらの使用
|
|
US11882815B2
(en)
|
2016-06-15 |
2024-01-30 |
University Of Massachusetts |
Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
|
|
CA2971303A1
(en)
|
2016-06-21 |
2017-12-21 |
Bamboo Therapeutics, Inc. |
Optimized mini-dystrophin genes and expression cassettes and their use
|
|
WO2018009814A1
(en)
|
2016-07-08 |
2018-01-11 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for treatment of disorders and diseases involving rdh12
|
|
US12214056B2
(en)
|
2016-07-19 |
2025-02-04 |
Duke University |
Therapeutic applications of CPF1-based genome editing
|
|
WO2018022511A1
(en)
|
2016-07-25 |
2018-02-01 |
The Trustees Of The University Of Pennsylvania |
Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof
|
|
EP3491008A2
(en)
*
|
2016-07-26 |
2019-06-05 |
BioMarin Pharmaceutical Inc. |
Novel adeno-associated virus capsid proteins
|
|
US11834490B2
(en)
|
2016-07-28 |
2023-12-05 |
Alpine Immune Sciences, Inc. |
CD112 variant immunomodulatory proteins and uses thereof
|
|
US11471488B2
(en)
|
2016-07-28 |
2022-10-18 |
Alpine Immune Sciences, Inc. |
CD155 variant immunomodulatory proteins and uses thereof
|
|
EP3491013A1
(en)
|
2016-07-28 |
2019-06-05 |
Alpine Immune Sciences, Inc. |
Cd155 variant immunomodulatory proteins and uses thereof
|
|
CN116286986A
(zh)
|
2016-07-29 |
2023-06-23 |
加利福尼亚大学董事会 |
具有变异衣壳的腺相关病毒病毒体和其使用方法
|
|
EP3500667A4
(en)
|
2016-08-18 |
2020-09-02 |
The Regents of the University of California |
GENOMIC ENGINEERING OF CRISPR-CAS THROUGH A MODULAR AAV DELIVERY SYSTEM
|
|
WO2018044933A1
(en)
|
2016-08-30 |
2018-03-08 |
The Regents Of The University Of California |
Methods for biomedical targeting and delivery and devices and systems for practicing the same
|
|
US10457940B2
(en)
*
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
|
AU2017341849B2
(en)
|
2016-10-13 |
2024-03-21 |
University Of Massachusetts |
AAV capsid designs
|
|
EP4338799A3
(en)
|
2016-10-18 |
2024-06-05 |
Regents of the University of Minnesota |
Tumor infiltrating lymphocytes and methods of therapy
|
|
EP3528785A4
(en)
|
2016-10-19 |
2020-12-02 |
Adverum Biotechnologies, Inc. |
MODIFIED AAV CASPIDS AND USES THEREOF
|
|
US20200040059A1
(en)
|
2016-10-20 |
2020-02-06 |
Alpine Immune Sciences, Inc. |
Secretable variant immunomodulatory proteins and engineered cell therapy
|
|
EP3535396A1
(en)
|
2016-11-01 |
2019-09-11 |
Novartis AG |
Methods and compositions for enhancing gene editing
|
|
US20190328846A1
(en)
|
2016-12-01 |
2019-10-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Pharmaceutical compositions for the treatment of retinal degenerative diseases
|
|
MX2019007873A
(es)
|
2016-12-30 |
2019-11-18 |
Univ Pennsylvania |
Terapia génica para tratar la enfermedad de wilson.
|
|
MX2019007876A
(es)
|
2016-12-30 |
2019-10-15 |
Univ Pennsylvania |
Terapia genetica para tratar fenilcetonuria.
|
|
EP3570895A1
(en)
|
2017-01-17 |
2019-11-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of expressing a polynucleotide of interest in the cone photoreceptors
|
|
US11535866B2
(en)
|
2017-02-01 |
2022-12-27 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating citrullenemia
|
|
WO2018148462A1
(en)
|
2017-02-09 |
2018-08-16 |
Indapta Therapeutics, Inc. |
Engineered natural killer (nk) cells and compositions and methods thereof
|
|
AU2018220212A1
(en)
|
2017-02-20 |
2019-08-08 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating familial hypercholesterolemia
|
|
CA3054131C
(en)
|
2017-02-21 |
2021-05-25 |
University Of Florida Research Foundation, Incorporated |
Modified aav capsid proteins and uses thereof
|
|
US11518991B2
(en)
|
2017-02-24 |
2022-12-06 |
Georg-August-Universitaet Goettingen Stiftung Oeffentlichen Rechts, Universitaetsmedizin |
Method for re-expression of different hypermethylated genes involved in fibrosis, like hypermethylated RASAL1 and use thereof in treatment of fibrosis as well as kit of parts for re-expression of hypermethylated genes including RASAL1 in a subject
|
|
PT3589730T
(pt)
|
2017-02-28 |
2024-02-28 |
Univ Pennsylvania |
Vetor de vírus adenoassociado (aav) de clado f e suas utilizações
|
|
JOP20190200A1
(ar)
|
2017-02-28 |
2019-08-27 |
Univ Pennsylvania |
تركيبات نافعة في معالجة ضمور العضل النخاعي
|
|
CN110573523A
(zh)
|
2017-02-28 |
2019-12-13 |
宾夕法尼亚州大学信托人 |
基于aav载体的流感疫苗
|
|
KR20240104196A
(ko)
|
2017-03-01 |
2024-07-04 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
안구 장애에 대한 유전자 치료
|
|
EP3589311A1
(en)
|
2017-03-02 |
2020-01-08 |
Genethon |
Method for removing anti-aav antibodies from a blood-derived composition
|
|
EP3596114A2
(en)
|
2017-03-16 |
2020-01-22 |
Alpine Immune Sciences, Inc. |
Cd80 variant immunomodulatory proteins and uses thereof
|
|
KR20240123406A
(ko)
|
2017-03-16 |
2024-08-13 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Pd-l1 리간드 변이체 면역조절 단백질 및 그의 용도
|
|
US11732022B2
(en)
|
2017-03-16 |
2023-08-22 |
Alpine Immune Sciences, Inc. |
PD-L2 variant immunomodulatory proteins and uses thereof
|
|
EP3601558A4
(en)
|
2017-03-24 |
2021-01-06 |
Lankenau Institute for Medical Research |
Methods and compositions for inducible extracellular membrane capture of monoclonal immunoglobulins secreted by hybridomas
|
|
US20210108197A1
(en)
|
2017-03-31 |
2021-04-15 |
Staidson (Beijing) Biopharmaceuticals Co., Ltd. |
Shrna expression cassette, polynucleotide sequence carrying same, and application thereof
|
|
WO2018189208A1
(en)
|
2017-04-10 |
2018-10-18 |
Genethon |
Antisense targeting dynamin 2 and use for the treatment of centronuclear myopathies and neuropathies
|
|
KR20240093919A
(ko)
|
2017-04-14 |
2024-06-24 |
리젠엑스바이오 인크. |
인간 뉴런 또는 신경교 세포에 의해 생성된 재조합 인간 이두로네이트-2 설파타제(ids)를 이용한 뮤코다당증 ii형의 치료
|
|
AU2018255293B2
(en)
*
|
2017-04-17 |
2024-03-07 |
University Of Florida Research Foundation, Incorporated |
Regulation of RAN translation by PKR and eIF2a-P pathways
|
|
EP3634986A4
(en)
|
2017-04-24 |
2021-09-08 |
The Trustees of The University of Pennsylvania |
GENE THERAPY FOR EYE DISORDERS
|
|
MX2019013172A
(es)
|
2017-05-05 |
2020-09-07 |
Voyager Therapeutics Inc |
Composiciones y metodos para tratar la enfermedad de huntington.
|
|
WO2018204786A1
(en)
|
2017-05-05 |
2018-11-08 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (als)
|
|
EP3622073A4
(en)
|
2017-05-09 |
2021-01-06 |
University of Massachusetts |
Methods of treating amyotrophic lateral sclerosis (als)
|
|
AU2018265414B2
(en)
|
2017-05-10 |
2022-01-20 |
Massachusetts Eye And Ear Infirmary |
Methods and compositions for modifying assembly-activating protein (APP)-dependence of viruses
|
|
SG11201910015SA
(en)
|
2017-05-11 |
2019-11-28 |
Univ Pennsylvania |
Gene therapy for neuronal ceroid lipofuscinoses
|
|
WO2018218359A1
(en)
|
2017-05-31 |
2018-12-06 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating peroxisomal disorders
|
|
WO2018232149A1
(en)
|
2017-06-14 |
2018-12-20 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for ocular disorders
|
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
|
EP3645021A4
(en)
*
|
2017-06-30 |
2021-04-21 |
Intima Bioscience, Inc. |
ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
|
|
AU2018290954B2
(en)
|
2017-06-30 |
2023-07-13 |
The Regents Of The University Of California |
Adeno-associated virus virions with variant capsids and methods of use thereof
|
|
BR112020000063A2
(pt)
|
2017-07-06 |
2020-07-14 |
The Trustees Of The University Of Pennsylvania |
terapia gênica mediada por aav9 para tratamento de mucopolissacaridose tipo i
|
|
CA3069045A1
(en)
|
2017-07-07 |
2019-01-10 |
Genethon |
Novel polynucleotides encoding a human fkrp protein
|
|
JP7229989B2
(ja)
|
2017-07-17 |
2023-02-28 |
ボイジャー セラピューティクス インコーポレイテッド |
軌道アレイガイドシステム
|
|
WO2019021233A1
(en)
|
2017-07-27 |
2019-01-31 |
Novartis Ag |
TREM2 VARIANTS RESISTANT TO SHEDDASE
|
|
AU2018311069A1
(en)
|
2017-08-03 |
2020-02-20 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of AAV
|
|
EP3676373A4
(en)
|
2017-08-28 |
2021-06-09 |
The Regents of The University of California |
Adeno-associated virus capsid variants and methods of use thereof
|
|
KR20250011726A
(ko)
|
2017-09-20 |
2025-01-21 |
4디 몰레큘러 테라퓨틱스 아이엔씨. |
아데노-관련 바이러스 변이체 캡시드 및 그 용도
|
|
EP3684937A4
(en)
|
2017-09-22 |
2021-06-02 |
University of Massachusetts |
NEW DUAL SOD1 EXPRESSION VECTORS AND RELATED USES
|
|
AU2018335752B2
(en)
|
2017-09-22 |
2025-04-10 |
Christian HINDERER |
Gene therapy for treating Mucopolysaccharidosis type ii
|
|
US11903910B2
(en)
|
2017-09-26 |
2024-02-20 |
University Of Florida Research Foundation, Incorporated |
Use of metformin and analogs thereof to reduce RAN protein levels in the treatment of neurological disorders
|
|
MX2020003042A
(es)
|
2017-09-29 |
2020-11-18 |
Voyager Therapeutics Inc |
Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa.
|
|
US11434502B2
(en)
|
2017-10-16 |
2022-09-06 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (ALS)
|
|
WO2019079242A1
(en)
|
2017-10-16 |
2019-04-25 |
Voyager Therapeutics, Inc. |
TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
|
|
CA3079568A1
(en)
|
2017-10-18 |
2019-04-25 |
Regenxbio Inc. |
Fully-human post-translationally modified antibody therapeutics
|
|
WO2019079520A2
(en)
|
2017-10-18 |
2019-04-25 |
Alpine Immune Sciences, Inc. |
ICOS VARIANT LIGAND IMMUNOMODULATORY IMMUNOMODULATORY PROTEINS, COMPOSITIONS AND METHODS THEREOF
|
|
EP3697449A1
(en)
|
2017-10-18 |
2020-08-26 |
REGENXBIO Inc. |
Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified vegf-trap
|
|
WO2019077159A1
(en)
|
2017-10-20 |
2019-04-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
METHODS OF EXPRESSING POLYNUCLEOTIDE OF INTEREST IN CONE PHOTORECCEPTORS OF A SUBJECT COMPRISING SUB-RETINAL ADMINISTRATION OF A THERAPEUTICALLY EFFECTIVE AMOUNT OF A RECOMBINANT AAV9 DERIVATIVE VECTOR
|
|
CR20200282A
(es)
|
2017-11-27 |
2021-02-18 |
4D Molecular Therapeutics Inc |
Cápsides variantes de virus adenoasociados y su uso para inhibir la angiogénesis
|
|
WO2019108857A1
(en)
|
2017-11-30 |
2019-06-06 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for mucopolysaccharidosis iiia
|
|
JP7384797B2
(ja)
|
2017-11-30 |
2023-11-21 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
ムコ多糖症ｉｉｉｂ型のための遺伝子療法
|
|
BR112020012336A2
(pt)
|
2017-12-19 |
2021-03-30 |
Akouos, Inc. |
Administração de anticorpos terapêuticos mediada por aav para o ouvido interno
|
|
EP3735417A1
(en)
|
2018-01-03 |
2020-11-11 |
Alpine Immune Sciences, Inc. |
Multi-domain immunomodulatory proteins and methods of use thereof
|
|
CA3088323A1
(en)
|
2018-01-17 |
2019-07-25 |
Adrenas Therapeutics, Inc. |
Adeno-associated virus gene therapy for 21-hydroxylase deficiency
|
|
BR112020015798A2
(pt)
|
2018-02-01 |
2021-03-09 |
Homology Medicines, Inc. |
Composições de vírus adeno-associado para restaurar função de gene da pah e métodos de uso das mesmas
|
|
US10610606B2
(en)
|
2018-02-01 |
2020-04-07 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
|
|
EP3755795A4
(en)
|
2018-02-19 |
2022-07-20 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for restoring f8 gene function and methods of use thereof
|
|
KR102848518B1
(ko)
*
|
2018-02-27 |
2025-08-22 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
캡시드 탈아미드화가 감소된 신규 아데노-연관 바이러스(aav) 벡터 및 이의 용도
|
|
CN112352050A
(zh)
*
|
2018-02-27 |
2021-02-09 |
宾夕法尼亚州大学信托人 |
新颖腺相关病毒（aav）载体、具有降低的衣壳脱酰胺化的aav载体及其用途
|
|
KR102834868B1
(ko)
*
|
2018-03-16 |
2025-07-17 |
더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 |
캡시드 변형에 의한 증가하는 조직 특정 유전자 전달
|
|
CA3094465A1
(en)
|
2018-04-03 |
2019-10-10 |
Stridebio, Inc. |
Virus vectors for targeting ophthalmic tissues
|
|
CN112272672A
(zh)
|
2018-04-03 |
2021-01-26 |
斯特里迪比奥公司 |
抗体逃避性病毒载体
|
|
SG11202009451VA
(en)
|
2018-04-03 |
2020-10-29 |
Stridebio Inc |
Antibody-evading virus vectors
|
|
WO2019195701A1
(en)
|
2018-04-05 |
2019-10-10 |
Massachusetts Eye And Ear Infirmary |
Methods of making and using combinatorial barcoded nucleic acid libraries having defined variation
|
|
BR112020020223A2
(pt)
|
2018-04-05 |
2021-01-19 |
Genethon |
Sorotipo de vírus adeno-associado híbrido recombinante entre aav9 e aavrh74 com tropismo pelo fígado reduzido
|
|
CN112601454B
(zh)
|
2018-04-16 |
2023-10-27 |
宾夕法尼亚州大学信托人 |
用于治疗杜兴肌营养不良的组合物和方法
|
|
KR20210009317A
(ko)
|
2018-04-18 |
2021-01-26 |
더 트러스티스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 |
미토콘드리아 dna 고갈 증후군을 포함하는 불균형 뉴클레오타이드 풀에 의해 초래된 질환에 대한 유전자 요법
|
|
MX2020011386A
(es)
|
2018-04-27 |
2021-01-29 |
Spacecraft Seven Llc |
Terapia genica para la degeneracion del snc.
|
|
CA3098566A1
(en)
|
2018-04-29 |
2019-11-07 |
Zhuchun WU |
Systems and methods of spectrophotometry for the determination of genome content, capsid content and full/empty ratios of adeno-associated virus particles
|
|
CA3098565A1
(en)
|
2018-04-29 |
2019-11-07 |
Claire G. ZHANG |
Scalable clarification process for recombinant aav production
|
|
US20210207168A1
(en)
|
2018-05-08 |
2021-07-08 |
Rutgers, The State University Of New Jersey |
Aav-compatible laminin-linker polymerization proteins
|
|
EP3790627A2
(en)
|
2018-05-09 |
2021-03-17 |
BioMarin Pharmaceutical Inc. |
Methods of treating phenylketonuria
|
|
KR20210010491A
(ko)
|
2018-05-11 |
2021-01-27 |
매사추세츠 아이 앤드 이어 인퍼머리 |
아데노-연관 바이러스의 간-특이적 향성
|
|
TW202005978A
(zh)
|
2018-05-14 |
2020-02-01 |
美商拜奧馬林製藥公司 |
新穎肝靶向腺相關病毒載體
|
|
EP3794126A1
(en)
|
2018-05-15 |
2021-03-24 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of parkinson's disease
|
|
WO2019222329A1
(en)
|
2018-05-15 |
2019-11-21 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
EP3813845A4
(en)
|
2018-05-15 |
2022-10-26 |
President And Fellows Of Harvard College |
Viral vectors exhibiting improved gene delivery properties
|
|
TWI869346B
(zh)
|
2018-05-30 |
2025-01-11 |
瑞士商諾華公司 |
Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
|
|
AU2019282239B2
(en)
|
2018-06-04 |
2024-06-06 |
Calidi Biotherapeutics (Nevada), Inc. |
Cell-based vehicles for potentiation of viral therapy
|
|
US11505782B2
(en)
|
2018-06-04 |
2022-11-22 |
Calidi Biotherapeutics, Inc. |
Cell-based vehicles for potentiation of viral therapy
|
|
WO2019236995A1
(en)
|
2018-06-08 |
2019-12-12 |
University Of Massachusetts |
Antisense oligonucleotides to restore dysferlin protein expression in dysferlinopathy patient cells
|
|
US20220403001A1
(en)
|
2018-06-12 |
2022-12-22 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
EP3807404A1
(en)
|
2018-06-13 |
2021-04-21 |
Voyager Therapeutics, Inc. |
Engineered 5' untranslated regions (5' utr) for aav production
|
|
IL319002A
(en)
|
2018-06-14 |
2025-04-01 |
Regenxbio Inc |
Anion exchange chromatography for recombinant AAV production
|
|
US12065476B2
(en)
|
2018-06-15 |
2024-08-20 |
Alpine Immune Sciences, Inc. |
PD-1 variant immunomodulatory proteins and uses thereof
|
|
GB201811368D0
(en)
|
2018-07-11 |
2018-08-29 |
Ucb Biopharma Sprl |
Antibody
|
|
MX2021000443A
(es)
|
2018-07-12 |
2021-05-28 |
Spacecraft Seven Llc |
Vectores de terapia génica para el tratamiento de la enfermedad de danon.
|
|
JP7413629B2
(ja)
|
2018-07-17 |
2024-01-16 |
ヘリックスミス カンパニー， リミテッド |
Ｉｇｆ－１異型体を発現させるｄｎａコンストラクトを用いた神経病症の治療
|
|
WO2020018691A1
(en)
*
|
2018-07-18 |
2020-01-23 |
The General Hospital Corporation |
Modified t cells and methods of their use
|
|
JP2021530548A
(ja)
|
2018-07-24 |
2021-11-11 |
ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics, Inc. |
遺伝子治療製剤を生産するための系および方法
|
|
WO2020028751A2
(en)
|
2018-08-03 |
2020-02-06 |
Voyager Therapeutics, Inc. |
Aav variants with enhanced tropism
|
|
WO2020033842A1
(en)
|
2018-08-10 |
2020-02-13 |
Regenxbio Inc. |
Scalable method for recombinant aav production
|
|
CA3109804A1
(en)
|
2018-08-16 |
2020-02-20 |
The Regents Of The University Of California |
Chemically and photochemically initiated cell membrane blebbing to induce cell vesicle production, modifications thereof, and uses thereof
|
|
WO2020047161A2
(en)
|
2018-08-28 |
2020-03-05 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
|
BR112021003897A2
(pt)
|
2018-08-30 |
2021-05-25 |
Tenaya Therapeutics, Inc. |
reprogramação de células cardíacas com miocarina e asci1
|
|
JP7624724B2
(ja)
|
2018-09-26 |
2025-01-31 |
カリフォルニア インスティテュート オブ テクノロジー |
標的遺伝子療法のためのアデノ随伴ウイルス組成物
|
|
SG11202103151RA
(en)
|
2018-09-28 |
2021-04-29 |
Voyager Therapeutics Inc |
Frataxin expression constructs having engineered promoters and methods of use thereof
|
|
US12472268B2
(en)
|
2018-10-01 |
2025-11-18 |
Ultragenyx Pharmaceutical Inc. |
Gene therapy for treating propionic acidemia
|
|
KR102821650B1
(ko)
|
2018-10-01 |
2025-06-16 |
토루 미야자키 |
신경변성 질환 치료제
|
|
MX2021003869A
(es)
|
2018-10-01 |
2021-09-08 |
Univ Pennsylvania |
Composiciones útiles para tratar la gangliosidosis gm1.
|
|
CN119684417A
(zh)
|
2018-10-02 |
2025-03-25 |
沃雅戈治疗公司 |
重新定向aav衣壳的嗜性
|
|
TW202035689A
(zh)
|
2018-10-04 |
2020-10-01 |
美商航海家醫療公司 |
測量病毒載體粒子的效價及強度之方法
|
|
CN113166731A
(zh)
*
|
2018-10-05 |
2021-07-23 |
沃雅戈治疗公司 |
编码aav生产蛋白的工程化核酸构建体
|
|
US20210371470A1
(en)
|
2018-10-12 |
2021-12-02 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
|
AU2019362833A1
(en)
|
2018-10-15 |
2021-04-29 |
Regenxbio Inc. |
Method for measuring the infectivity of replication defective viral vectors and viruses
|
|
EP3867389A1
(en)
|
2018-10-15 |
2021-08-25 |
Voyager Therapeutics, Inc. |
Expression vectors for large-scale production of raav in the baculovirus/sf9 system
|
|
JP7558575B2
(ja)
|
2018-10-22 |
2024-10-01 |
ユニバーシティ オブ ロチェスター |
レトロウイルスインテグラーゼ－Ｃａｓ９融合タンパク質を使用した指向性非相同ＤＮＡ挿入によるゲノム編集
|
|
EP3870600A1
(en)
|
2018-10-24 |
2021-09-01 |
Obsidian Therapeutics, Inc. |
Er tunable protein regulation
|
|
JP7329593B2
(ja)
|
2018-11-06 |
2023-08-18 |
カリディ・バイオセラピューティクス・インコーポレイテッド |
細胞媒介性腫瘍溶解性ウイルス治療のための増強された系
|
|
SG11202105030VA
(en)
|
2018-11-16 |
2021-06-29 |
Astellas Pharma Inc |
Method for treating muscular dystrophy by targeting utrophin gene
|
|
CN113891934A
(zh)
|
2018-11-21 |
2022-01-04 |
因达普塔治疗公司 |
扩增天然杀伤（nk）细胞子集的方法以及相关组合物和方法
|
|
CN113226380A
(zh)
*
|
2018-11-30 |
2021-08-06 |
诺华股份有限公司 |
Aav病毒载体及其用途
|
|
KR20210135987A
(ko)
|
2018-11-30 |
2021-11-16 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Cd86 변이체 면역조절 단백질 및 그의 용도
|
|
EP3890786A4
(en)
|
2018-12-05 |
2022-08-31 |
Abeona Therapeutics Inc. |
RECOMBINANT ADENO-ASSOCIATED VIRUS VECTOR FOR GENE RELEASE
|
|
US20220089670A1
(en)
|
2018-12-28 |
2022-03-24 |
University Of Rochester |
Gene Therapy for BEST1 Dominant Mutations
|
|
PT3906066T
(pt)
|
2019-01-04 |
2024-02-06 |
Ultragenyx Pharmaceutical Inc |
Constructos de terapia génica para o tratamento da doença de wilson
|
|
AU2020208346A1
(en)
|
2019-01-14 |
2021-07-29 |
University Of Rochester |
Targeted nuclear RNA cleavage and polyadenylation with CRISPR-cas
|
|
CA3125770A1
(en)
|
2019-01-18 |
2020-07-23 |
Voyager Therapeutics, Inc. |
Methods and systems for producing aav particles
|
|
EP3917566A4
(en)
|
2019-01-31 |
2022-10-26 |
Oregon Health & Science University |
METHODS OF USING TRANSCRIPTION-DEPENDENT DIRECTED EVOLUTION OF AAV CAPSIDS
|
|
JP7637058B2
(ja)
|
2019-02-22 |
2025-02-27 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
Ｇｒｎ関連成人発症性神経変性の治療のための組換えアデノ随伴ウイルス
|
|
JP2022521025A
(ja)
|
2019-02-25 |
2022-04-04 |
ノバルティス アーゲー |
Ｂｉｅｔｔｉクリスタリン網膜症を治療するための組成物及び方法
|
|
US20220154211A1
(en)
|
2019-02-25 |
2022-05-19 |
Novartis Ag |
Compositions and methods to treat bietti crystalline dystrophy
|
|
CN114040980A
(zh)
|
2019-02-26 |
2022-02-11 |
宾夕法尼亚州大学信托人 |
可用于治疗克拉伯病的组合物
|
|
US12024709B2
(en)
|
2019-02-27 |
2024-07-02 |
Actym Therapeutics, Inc. |
Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
|
|
BR112021016728A2
(pt)
|
2019-02-27 |
2022-01-11 |
Actym Therapeutics Inc |
Bactérias imunostimulatórias projetadas para colonizar tumores, residentes em tumores células imunológicas e o microambiente tumoral
|
|
SG11202110146VA
(en)
|
2019-03-21 |
2021-10-28 |
Stridebio Inc |
Recombinant adeno-associated virus vectors
|
|
CA3130196A1
(en)
|
2019-03-25 |
2020-10-01 |
Isabelle Richard |
Production of large-sized quasidystrophins using overlapping aav vectors
|
|
AU2020253435A1
(en)
|
2019-04-01 |
2021-11-18 |
Tenaya Therapeutics, Inc. |
Adeno-associated virus with engineered capsid
|
|
AU2020253462A1
(en)
|
2019-04-03 |
2021-10-28 |
Regenxbio Inc. |
Gene therapy for eye pathologies
|
|
TW202102526A
(zh)
|
2019-04-04 |
2021-01-16 |
美商銳進科斯生物股份有限公司 |
重組腺相關病毒及其用途
|
|
SI3953483T1
(sl)
|
2019-04-11 |
2024-02-29 |
Regenxbio Inc. |
Postopki gelske izključitvene kromatografije za karakterizacijo spojin rekombinantnih adeno-povezanih virusov
|
|
AR118734A1
(es)
|
2019-04-19 |
2021-10-27 |
Regenxbio Inc |
Formulaciones y métodos de vectores de virus adenoasociados
|
|
SG11202111414RA
(en)
|
2019-04-24 |
2021-11-29 |
Regenxbio Inc |
Fully-human post-translationally modified antibody therapeutics
|
|
WO2020223280A1
(en)
|
2019-04-29 |
2020-11-05 |
Voyager Therapeutics, Inc. |
Aav variants with enhanced tropism
|
|
WO2020223274A1
(en)
|
2019-04-29 |
2020-11-05 |
Voyager Therapeutics, Inc. |
SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS
|
|
JP7644026B2
(ja)
*
|
2019-04-29 |
2025-03-11 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
新規ａａｖカプシドおよびそれを含む組成物
|
|
KR20220020261A
(ko)
|
2019-05-03 |
2022-02-18 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
이염성 백질이영양증의 치료에 유용한 조성물
|
|
EP3966227A1
(en)
|
2019-05-07 |
2022-03-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
|
|
US20200362368A1
(en)
|
2019-05-14 |
2020-11-19 |
Biomarin Pharmaceutical Inc. |
Methods of redosing gene therapy vectors
|
|
US20220233721A1
(en)
|
2019-05-28 |
2022-07-28 |
Astellas Pharma Inc. |
Method for treating muscular dystrophy by targeting dmpk gene
|
|
EP3976806A1
(en)
|
2019-05-30 |
2022-04-06 |
Solidus Biosciences, Inc. |
Recombinant herpesvirales vector
|
|
EP3990030A1
(en)
|
2019-06-27 |
2022-05-04 |
Pfizer Inc. |
Methods of treating duchenne muscular dystrophy using aav mini-dystrophin gene therapy
|
|
KR20220069917A
(ko)
|
2019-07-02 |
2022-05-27 |
엠6피 테라퓨틱스 (스위처랜드) 엘엘씨 |
리소좀 축적 장애의 치료를 위한 벡터 조성물 및 이의 사용 방법
|
|
WO2021005223A1
(en)
|
2019-07-10 |
2021-01-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of epilepsy
|
|
WO2021007515A1
(en)
|
2019-07-11 |
2021-01-14 |
Tenaya Therapeutics, Inc. |
Cardiac cell reprogramming with micrornas and other factors
|
|
JP7654626B2
(ja)
|
2019-07-11 |
2025-04-01 |
サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィック |
化学修飾型アデノ随伴ウイルス
|
|
US10557149B1
(en)
|
2019-07-15 |
2020-02-11 |
Vigene Biosciences, Inc. |
Recombinantly-modified adeno-associated virus helper vectors and their use to improve the packaging efficiency of recombinantly-modified adeno-associated virus
|
|
US10801042B1
(en)
|
2019-07-15 |
2020-10-13 |
Vigene Biosciences, Inc. |
Use of ion concentrations to increase the packaging efficiency of recombinant adeno-associated virus
|
|
US10653731B1
(en)
|
2019-07-15 |
2020-05-19 |
Vigene Biosciences Inc. |
Recombinantly-modified adeno-associated virus (rAAV) having improved packaging efficiency
|
|
WO2021016453A1
(en)
|
2019-07-23 |
2021-01-28 |
University Of Rochester |
Targeted rna cleavage with crispr-cas
|
|
EP4007814A1
(en)
|
2019-07-26 |
2022-06-08 |
Akouos, Inc. |
Methods of treating hearing loss using a secreted target protein
|
|
CA3145112A1
(en)
|
2019-07-26 |
2021-02-04 |
Chunping Qiao |
Engineered nucleic acid regulatory element and methods of uses thereof
|
|
US20220290182A1
(en)
|
2019-08-09 |
2022-09-15 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
|
MX2022001859A
(es)
|
2019-08-16 |
2022-03-11 |
Modalis Therapeutics Corp |
Metodo para el tratamiento de la distrofia muscular al fijar como blanco el gen lama1.
|
|
WO2021034920A1
(en)
*
|
2019-08-20 |
2021-02-25 |
St. Jude Children's Research Hospital, Inc. |
SCHIZOPHRENIA-RELATED MICRODELETION GENE 2510002D24Rik IS ESSENTIAL FOR SOCIAL MEMORY
|
|
MX2022002366A
(es)
|
2019-08-26 |
2022-07-19 |
Regenxbio Inc |
Tratamiento de la retinopatía diabética con fab anti-vegf completamente humano modificado postraduccionalmente.
|
|
US20220307013A1
(en)
|
2019-08-30 |
2022-09-29 |
The Regents Of The University Of California |
Gene fragment overexpression screening methodologies, and uses thereof
|
|
US20230092895A1
(en)
|
2019-08-30 |
2023-03-23 |
Obsidian Therapeutics, Inc. |
Tandem cd19 car-based compositions and methods for immunotherapy
|
|
WO2021046155A1
(en)
|
2019-09-03 |
2021-03-11 |
Voyager Therapeutics, Inc. |
Vectorized editing of nucleic acids to correct overt mutations
|
|
WO2021046451A1
(en)
|
2019-09-06 |
2021-03-11 |
Obsidian Therapeutics, Inc. |
Compositions and methods for dhfr tunable protein regulation
|
|
CA3150330A1
(en)
|
2019-09-13 |
2021-03-18 |
Peter D. YURCHENCO |
Aav-compatible laminin-linker polymerization proteins
|
|
EP4031578A1
(en)
|
2019-09-18 |
2022-07-27 |
Novartis AG |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與ｅｎｔｐｄ２抗體之組合療法
|
|
CN114521143B
(zh)
|
2019-09-19 |
2025-03-14 |
吉尼松公司 |
减轻fkrp心脏毒性的基因治疗表达系统
|
|
EP4031562A4
(en)
|
2019-09-20 |
2023-11-01 |
University of Florida Research Foundation, Incorporated |
DETECTION OF ANTIBODIES AGAINST RAN PROTEINS FROM SERUM AND TISSUE LYSATES
|
|
US20220347298A1
(en)
|
2019-10-04 |
2022-11-03 |
Ultragenyx Pharmaceutical Inc. |
Methods for improved therapeutic use of recombinant aav
|
|
AU2020362119A1
(en)
|
2019-10-07 |
2022-05-26 |
Regenxbio Inc. |
Adeno-associated virus vector pharmaceutical composition and methods
|
|
US20220362402A1
(en)
|
2019-10-08 |
2022-11-17 |
Exhaura, Ltd. |
Compositions and methods for ocular therapy
|
|
CN114761546A
(zh)
|
2019-10-08 |
2022-07-15 |
波士顿学院董事会 |
含有多个不同非天然氨基酸的蛋白质以及制备和使用此类蛋白质的方法
|
|
US20240108754A1
(en)
|
2019-10-14 |
2024-04-04 |
Duke University |
Compositions comprising novel prokaryotic sodium channels and associated methods
|
|
EP4045525A1
(en)
*
|
2019-10-17 |
2022-08-24 |
Stridebio, Inc. |
Adeno-associated viral vectors for treatment of niemann-pick disease type c
|
|
WO2021092300A1
(en)
*
|
2019-11-08 |
2021-05-14 |
President And Fellows Of Harvard College |
Viral capsid polypeptides
|
|
US20230002451A1
(en)
*
|
2019-11-08 |
2023-01-05 |
President And Fellows Of Harvard College |
Viral capsid polypeptides
|
|
US20230016983A1
(en)
|
2019-11-19 |
2023-01-19 |
lNSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) |
Antisense oligonucleotides and thier use for the treatment of cancer
|
|
BR112022009895A2
(pt)
*
|
2019-11-28 |
2022-08-09 |
Regenxbio Inc |
Construtos de terapia de gene de microdistrofina e usos dos mesmos
|
|
KR20220110781A
(ko)
*
|
2019-12-04 |
2022-08-09 |
상가모 테라퓨틱스, 인코포레이티드 |
재조합 aav를 생산하기 위한 신규 조성물 및 방법
|
|
US20230047424A1
(en)
|
2019-12-09 |
2023-02-16 |
Ucl Business Ltd |
Gene therapy composition and treatment for myh7-linked cardiomyopathy
|
|
IL293684A
(en)
|
2019-12-10 |
2022-08-01 |
Takeda Pharmaceuticals Co |
Adeno associated virus vectors for the treatment of hunter disease
|
|
JP2023509443A
(ja)
|
2019-12-31 |
2023-03-08 |
スワンバイオ セラピューティクス リミテッド |
改善されたａａｖ－ａｂｃｄ１コンストラクトならびに副腎白質ジストロフィー（ａｌｄ）および／または副腎脊髄ニューロパチー（ａｍｎ）の処置または予防のための使用
|
|
TW202140791A
(zh)
|
2020-01-13 |
2021-11-01 |
美商霍蒙拉奇醫藥公司 |
治療苯酮尿症之方法
|
|
CA3167685A1
(en)
|
2020-01-22 |
2021-07-29 |
Regenxbio Inc. |
Treatment of mucopolysaccharidosis i with fully-human glycosylated human alpha-l-iduronidase (idua)
|
|
AU2021212749A1
(en)
|
2020-01-29 |
2022-08-18 |
Regenxbio Inc. |
Treatment of mucopolysaccharidosis IVA
|
|
JP2023512242A
(ja)
|
2020-01-29 |
2023-03-24 |
レジェンクスバイオ インコーポレーテッド |
ヒト神経細胞またはヒトグリア細胞が産生した組換えヒトイズロン酸－２－スルファターゼ（ｉｄｓ）によるムコ多糖症ｉｉの治療
|
|
MX2022009462A
(es)
|
2020-02-02 |
2022-11-10 |
Univ Pennsylvania |
Composiciones útiles para tratar la gangliosidosis gm1.
|
|
WO2021158982A2
(en)
|
2020-02-07 |
2021-08-12 |
University Of Rochester |
Targeted translation of rna with crispr-cas13 to enhance protein synthesis
|
|
WO2021158964A1
(en)
|
2020-02-07 |
2021-08-12 |
University Of Rochester |
Ribozyme-mediated rna assembly and expression
|
|
BR112022015921A2
(pt)
|
2020-02-14 |
2022-10-04 |
Ultragenyx Pharmaceutical Inc |
Terapia gênica para tratar o transtorno de deficiência de cdkl5
|
|
JP2023515820A
(ja)
|
2020-02-28 |
2023-04-14 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
メープルシロップ尿症の遺伝子治療
|
|
IL295989A
(en)
|
2020-03-02 |
2022-10-01 |
Tenaya Therapeutics Inc |
Gene vector control using cardiomyocyte expression microRNA
|
|
CA3170369A1
(en)
|
2020-03-05 |
2022-04-14 |
Michal Shahar |
Methods and compositions for treating cancer with immune cells
|
|
CA3171066A1
(en)
|
2020-03-11 |
2021-09-16 |
Saar GILL |
Methods and composition for gene delivery using an engineered viral particle
|
|
US20230235353A1
(en)
*
|
2020-03-19 |
2023-07-27 |
Ultragenyx Pharmaceutical Inc. |
Compositions and methods for reducing reverse packaging of cap and rep sequences in recombinant aav
|
|
EP4127169A1
(en)
|
2020-03-27 |
2023-02-08 |
University of Rochester |
Targeted destruction of viral rna by crispr-cas13
|
|
WO2021191424A1
(en)
|
2020-03-27 |
2021-09-30 |
UCB Biopharma SRL |
Autonomous knob domain peptides
|
|
US20230103771A1
(en)
|
2020-03-27 |
2023-04-06 |
University Of Rochester |
CRISPR-Cas13 crRNA Arrays
|
|
EP4127189A1
(en)
|
2020-03-31 |
2023-02-08 |
Ultragenyx Pharmaceutical Inc. |
Gene therapy for treating propionic acidemia
|
|
WO2021202651A1
(en)
|
2020-04-01 |
2021-10-07 |
Voyager Therapeutics, Inc. |
Redirection of tropism of aav capsids
|
|
TW202204383A
(zh)
|
2020-04-10 |
2022-02-01 |
美商碩拿生物科學有限責任公司 |
用於治療蛋白質聚集病症之組合物及方法
|
|
KR20230020394A
(ko)
|
2020-04-15 |
2023-02-10 |
보이저 테라퓨틱스, 인크. |
Tau 결합 화합물
|
|
KR20230004719A
(ko)
*
|
2020-04-20 |
2023-01-06 |
테나야 테라퓨틱스, 인코포레이티드 |
조작된 캡시드를 갖는 아데노-연관 바이러스
|
|
JP2023523429A
(ja)
|
2020-04-22 |
2023-06-05 |
インダプタ セラピューティクス インコーポレイテッド |
ナチュラルキラー（ｎｋ）細胞組成物およびそれを生成させるための方法
|
|
AU2021265088A1
(en)
|
2020-04-28 |
2022-11-03 |
Sola Biosciences Llc |
Compositions and methods for the treatment of TDP-43 proteinopathies
|
|
KR20230029616A
(ko)
*
|
2020-05-05 |
2023-03-03 |
듀크 유니버시티 |
종간 호환가능한 아데노-관련 바이러스 조성물 및 이의 사용 방법
|
|
JP2023526310A
(ja)
|
2020-05-12 |
2023-06-21 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
導入遺伝子発現のｄｒｇ特異的低減のための組成物
|
|
AU2021271635A1
(en)
|
2020-05-12 |
2023-01-05 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of krabbe disease
|
|
EP4165194A2
(en)
|
2020-05-13 |
2023-04-19 |
Akouos, Inc. |
Compositions and methods for treating kcnq4-associated hearing loss
|
|
IL298001A
(en)
|
2020-05-13 |
2023-01-01 |
Voyager Therapeutics Inc |
Redirecting tropism of adeno-associated virus capsids
|
|
KR20230041965A
(ko)
|
2020-05-13 |
2023-03-27 |
아카우오스, 인크. |
Slc26a4-연관 청력손실을 치료하기 위한 조성물 및 방법
|
|
WO2021230385A1
(en)
|
2020-05-15 |
2021-11-18 |
Astellas Pharma Inc. |
Method for treating muscular dystrophy by targeting utrophin gene
|
|
WO2021236908A2
(en)
|
2020-05-20 |
2021-11-25 |
Biomarin Pharmaceutical Inc. |
Use of regulatory proteins for the production of adeno-associated virus
|
|
TW202208632A
(zh)
|
2020-05-27 |
2022-03-01 |
美商同源醫藥公司 |
用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法
|
|
WO2021247995A2
(en)
|
2020-06-04 |
2021-12-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating neuropathic pain
|
|
WO2021248038A1
(en)
|
2020-06-05 |
2021-12-09 |
Sola Biosciences Llc |
Compositions and methods for the treatment of synucleinopathies
|
|
CN115968302A
(zh)
|
2020-06-17 |
2023-04-14 |
宾夕法尼亚州大学信托人 |
用于治疗基因疗法患者的组合物和方法
|
|
CA3182313A1
(en)
|
2020-06-19 |
2021-12-23 |
Isabelle Richard |
Gene therapy expression system allowing an adequate expression in the muscles and in the heart of sgcg
|
|
JP2023532704A
(ja)
*
|
2020-07-03 |
2023-07-31 |
ジェネトン |
超可変領域スワッピングを通じて新規のハイブリッドａａｖカプシドを操作する方法
|
|
AU2021306697A1
(en)
*
|
2020-07-07 |
2023-02-09 |
The Board Of Regents Of The University Of Texas System |
Adeno-associated virus vector for dwarf open reading frame
|
|
BR112023000305A2
(pt)
|
2020-07-10 |
2023-03-21 |
Genethon |
Promotor, sistema de expressão e composição farmacêutica
|
|
WO2022011262A1
(en)
|
2020-07-10 |
2022-01-13 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for treating epilepsy
|
|
MX2023000658A
(es)
|
2020-07-13 |
2023-02-23 |
Univ Pennsylvania |
Composiciones utiles para el tratamiento de la enfermedad de charcot-marie-tooth.
|
|
WO2022015916A1
(en)
|
2020-07-15 |
2022-01-20 |
University Of Rochester |
Targeted rna cleavage with dcasl3-rnase fusion proteins
|
|
US20230285596A1
(en)
|
2020-07-27 |
2023-09-14 |
Voyager Therapeutics, Inc |
Compositions and methods for the treatment of niemann-pick type c1 disease
|
|
AU2021315876A1
(en)
|
2020-07-27 |
2023-02-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
CN116121274B
(zh)
*
|
2020-07-29 |
2024-11-19 |
北京三诺佳邑生物技术有限责任公司 |
一组肝靶向新型腺相关病毒的获得及其应用
|
|
EP4192514A1
(en)
|
2020-08-06 |
2023-06-14 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
|
US20230340041A1
(en)
|
2020-08-17 |
2023-10-26 |
Massachusetts Institute Of Technology |
Shank3 gene therapy approaches
|
|
TW202227632A
(zh)
|
2020-08-19 |
2022-07-16 |
美商史崔德生物公司 |
用於治療雷特症候群之腺相關病毒載體
|
|
WO2022046815A1
(en)
|
2020-08-24 |
2022-03-03 |
The Trustees Of The University Of Pennsylvania |
Viral vectors encoding glp-1 receptor agonist fusions and uses thereof in treating metabolic diseases
|
|
WO2022046988A1
(en)
|
2020-08-26 |
2022-03-03 |
The Trustees Of The University Of Pennsylvania |
Recombinant adeno-associated virus for treatment of grn-associated adult-onset neurodegeneration
|
|
US20230323335A1
(en)
|
2020-09-04 |
2023-10-12 |
National University Corporation Kobe University |
Miniaturized cytidine deaminase-containing complex for modifying double-stranded dna
|
|
EP4213890A1
(en)
|
2020-09-15 |
2023-07-26 |
RegenxBio Inc. |
Vectorized lanadelumab and administration thereof
|
|
WO2022060916A1
(en)
|
2020-09-15 |
2022-03-24 |
Regenxbio Inc. |
Vectorized antibodies for anti-viral therapy
|
|
WO2022061002A1
(en)
|
2020-09-18 |
2022-03-24 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Novel adeno-associated viral (aav) vectors to treat hereditary methylmalonic acidemia (mma) caused by methylmalonyl-coa mutase (mmut) deficiency
|
|
US20230364206A1
(en)
|
2020-10-07 |
2023-11-16 |
Regenxbio Inc. |
Gene therapy for ocular manifestations of cln2 disease
|
|
AU2021358048A1
(en)
|
2020-10-07 |
2023-05-25 |
Regenxbio Inc. |
Formulations for suprachoroidal administration such as high viscosity formulations
|
|
WO2022076750A2
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns or muscle delivery
|
|
JP2023545722A
(ja)
|
2020-10-07 |
2023-10-31 |
リジェネックスバイオ インコーポレイテッド |
遺伝子治療剤の眼送達のためのアデノ随伴ウイルス
|
|
US20230414788A1
(en)
|
2020-10-07 |
2023-12-28 |
Regenxbio Inc. |
Formulations for suprachoroidal administration such as gel formulations
|
|
WO2022076591A1
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Formulations for suprachoroidal administration such as formulations with aggregate formation
|
|
US11781156B2
(en)
|
2020-10-09 |
2023-10-10 |
Tenaya Therapeutics, Inc. |
Plakophillin-2 gene therapy methods and compositions
|
|
KR20230118075A
(ko)
|
2020-10-09 |
2023-08-10 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
파브리병 치료를 위한 조성물 및 방법
|
|
CA3195553A1
(en)
|
2020-10-18 |
2022-04-21 |
Qiang Wang |
Improved adeno-associated virus (aav) vector and uses therefor
|
|
WO2022094157A1
(en)
|
2020-10-28 |
2022-05-05 |
Regenxbio Inc. |
Vectorized anti-cgrp and anti-cgrpr antibodies and administration thereof
|
|
EP4236999A1
(en)
|
2020-10-28 |
2023-09-06 |
RegenxBio Inc. |
Vectorized anti-tnf-alfa antibodies for ocular indications
|
|
WO2022094078A1
(en)
|
2020-10-28 |
2022-05-05 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of rett syndrome
|
|
US20230390418A1
(en)
|
2020-10-29 |
2023-12-07 |
Regenxbio Inc. |
Vectorized factor xii antibodies and administration thereof
|
|
KR20230098176A
(ko)
|
2020-10-29 |
2023-07-03 |
리젠엑스바이오 인크. |
안구 적응증을 위한 벡터화된 tnf-알파 길항제
|
|
KR20230078805A
(ko)
|
2020-11-02 |
2023-06-02 |
바이오마린 파머수티컬 인크. |
아데노-연관 바이러스의 농축 공정
|
|
CA3200401A1
(en)
|
2020-11-03 |
2022-05-12 |
Pfizer Inc. |
Methods for purification of aav vectors by anion exchange chromatography
|
|
TW202237850A
(zh)
|
2020-12-01 |
2022-10-01 |
賓州大學委員會 |
具有組織特異性靶向基序的新穎構成物及含有其之組成物
|
|
MX2023006445A
(es)
|
2020-12-01 |
2023-08-10 |
Univ Pennsylvania |
Composiciones y usos de estas para el tratamiento del síndrome de angelman.
|
|
AU2021391433A1
(en)
|
2020-12-01 |
2023-06-22 |
Akouos, Inc. |
Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms
|
|
WO2022130172A1
(en)
|
2020-12-15 |
2022-06-23 |
Pfizer Inc. |
Hilic uplc-ms method for separating and analyzing intact adeno-associated virus capsid proteins
|
|
AU2021403076A1
(en)
|
2020-12-16 |
2023-06-29 |
Regenxbio Inc. |
Method of producing a recombinant adeno-associated virus particle
|
|
WO2022137076A1
(en)
|
2020-12-23 |
2022-06-30 |
Pfizer Inc. |
Methods for purification of aav vectors by affinity chromatography
|
|
CA3203373A1
(en)
|
2020-12-29 |
2022-07-07 |
Emmanuel John Simons |
Compositions and methods for treating clrn1-associated hearing loss and/or vision loss
|
|
US20240309076A1
(en)
|
2020-12-29 |
2024-09-19 |
Regenxbio Inc. |
Tau-specific antibody gene therapy compositions, methods and uses thereof
|
|
TW202241479A
(zh)
|
2020-12-30 |
2022-11-01 |
美商安迅生物製藥公司 |
遞送外來抗原之溶瘤病毒及表現靶向外來抗原之嵌合受體之經工程化免疫細胞之組合療法
|
|
CN116981697A
(zh)
|
2021-01-14 |
2023-10-31 |
森迪生物科学公司 |
可分泌有效载荷调节
|
|
JP2024503895A
(ja)
|
2021-01-21 |
2024-01-29 |
リジェネクスバイオ インコーポレイテッド |
組換えポリペプチド及びウイルスの生成の改善
|
|
EP4281551A4
(en)
*
|
2021-01-25 |
2025-06-04 |
Trames Bio, Inc. |
ADENO-ASSOCIATED VIRUS CAPSIDS AND MANIPULATED LIGAND-GATED ION CHANNELS FOR THE TREATMENT OF FOCAL EPILEPSY AND NEUROPATHIC PAIN
|
|
AU2022214429A1
(en)
|
2021-02-01 |
2023-09-14 |
Tern Therapeutics, Llc |
Gene therapy for neuronal ceroid lipofuscinoses
|
|
US11926842B2
(en)
*
|
2021-02-02 |
2024-03-12 |
University Of Massachusetts |
Use of inverted terminal repeats (ITRS) from adeno-associated virus serotypes 8 and RH.39 in gene therapy vectors
|
|
JP2024506296A
(ja)
|
2021-02-05 |
2024-02-13 |
メイズ セラピューティクス， インコーポレイテッド |
スタッファーポリヌクレオチド配列を含むベクター
|
|
US20240115734A1
(en)
*
|
2021-02-09 |
2024-04-11 |
Affinia Therapeutics Inc. |
Recombinant aavs with improved tropism and specificity
|
|
US20240117328A1
(en)
|
2021-02-10 |
2024-04-11 |
Regenxbio Inc. |
Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids)
|
|
CA3209673A1
(en)
|
2021-02-26 |
2022-09-01 |
Rizwana ISLAM |
Composition and methods for the treatment of fabry disease
|
|
EP4301768A2
(en)
|
2021-03-03 |
2024-01-10 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
US20240141378A1
(en)
|
2021-03-03 |
2024-05-02 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
CA3212876A1
(en)
|
2021-03-19 |
2022-09-22 |
Adrenas Therapeutics, Inc. |
Gene therapies for 21-hydroxylase deficiency
|
|
WO2022208342A1
(en)
|
2021-04-01 |
2022-10-06 |
Pfizer Inc. |
Pharmaceutical compositions containing adeno-associated viral vector
|
|
CA3218333A1
(en)
|
2021-04-05 |
2022-10-13 |
Solid Biosciences Inc. |
Recombinant herpesvirales vector
|
|
CA3215141A1
(en)
|
2021-04-12 |
2022-10-20 |
James M. Wilson |
Compositions useful for treating spinal and bulbar muscular atrophy (sbma)
|
|
EP4334334A1
(en)
|
2021-04-23 |
2024-03-13 |
The Trustees of The University of Pennsylvania |
Novel compositions with brain-specific targeting motifs and compositions containing same
|
|
MX2023012511A
(es)
|
2021-04-23 |
2024-01-08 |
Univ Rochester |
Edición del genóma por inserción no homóloga de adn dirigida utilizando una proteína de fusión retroviral de integrasa-cas y métodos de tratamiento.
|
|
CA3216420A1
(en)
|
2021-04-26 |
2022-11-03 |
Seungil Han |
Adeno-associated viral vector capsids with improved tissue tropism
|
|
TW202309293A
(zh)
|
2021-04-26 |
2023-03-01 |
美商銳進科斯生物股份有限公司 |
用於治療肌縮蛋白症(dystrophinopathy)之微小肌縮蛋白基因療法給藥
|
|
US20240218397A1
(en)
|
2021-05-04 |
2024-07-04 |
Regenxbio Inc. |
Novel aav vectors and methods and uses thereof
|
|
US20240358857A1
(en)
|
2021-05-11 |
2024-10-31 |
Regenxbio Inc. |
Treatment of duchenne muscular dystrophy and combinations thereof
|
|
US20230056226A1
(en)
*
|
2021-06-08 |
2023-02-23 |
Nf2 Therapeutics, Inc. |
Compositions and methods for treating neurofibromatic disorders
|
|
WO2022266452A1
(en)
*
|
2021-06-18 |
2022-12-22 |
Dyno Therapeutics, Inc. |
Capsid variants and methods of using the same
|
|
CA3224755A1
(en)
|
2021-06-22 |
2022-12-29 |
Pfizer Inc. |
Production of adeno-associated virus vector in insect cells
|
|
US20240287493A1
(en)
*
|
2021-06-24 |
2024-08-29 |
University Of Utah Research Foundation |
Compositions and methods for treating pgm1 deficiency
|
|
AU2022301302A1
(en)
|
2021-07-01 |
2024-01-25 |
Indapta Therapeutics, Inc. |
Engineered natural killer (nk) cells and related methods
|
|
EP4367251A1
(en)
|
2021-07-08 |
2024-05-15 |
Tenaya Therapeutics, Inc. |
Optimized expression cassettes for gene therapy
|
|
US20240409955A1
(en)
|
2021-07-19 |
2024-12-12 |
New York University |
Auf1 combination therapies for treatment of muscle degenerative disease
|
|
EP4359551A4
(en)
*
|
2021-07-23 |
2025-09-24 |
Univ Duke |
ADENO-ASSOCIATED VIRUS COMPOSITIONS AND METHODS OF USE THEREOF
|
|
IL310515A
(en)
|
2021-07-30 |
2024-03-01 |
Toru Miyazaki |
Therapeutic agent for ischemic disease
|
|
MX2024001208A
(es)
|
2021-08-11 |
2024-04-22 |
Sana Biotechnology Inc |
Celulas primarias geneticamente modificadas para terapia celular alogenica.
|
|
EP4384544A1
(en)
|
2021-08-11 |
2024-06-19 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy
|
|
WO2023019225A2
(en)
|
2021-08-11 |
2023-02-16 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
|
|
AU2022325231A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
|
|
AU2022335593A1
(en)
*
|
2021-08-25 |
2024-03-14 |
Canbridge Pharmaceuticals, Inc. |
Aav particles comprising liver-tropic capsid protein and acid alpha-glucosidase and use to treat pompe disease
|
|
TW202330929A
(zh)
*
|
2021-08-25 |
2023-08-01 |
美商北海康成製藥有限公司 |
包含肝向性殼體蛋白質和α－半乳糖苷酶的ＡＡＶ顆粒及其治療法布立症的用途
|
|
IL311096A
(en)
|
2021-08-31 |
2024-04-01 |
Scout Bio Inc |
Antigen binding molecules and their uses
|
|
EP4405396A2
(en)
|
2021-09-20 |
2024-07-31 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
IL311572A
(en)
|
2021-09-30 |
2024-05-01 |
Akouos Inc |
Compositions and methods for treating kcnq4-associated hearing loss
|
|
US20240384298A1
(en)
|
2021-10-02 |
2024-11-21 |
The Trustees Of The University Of Pennsylvania |
Novel aav capsids and compositions containing same
|
|
WO2023060113A1
(en)
|
2021-10-05 |
2023-04-13 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
|
CN118202060A
(zh)
|
2021-10-05 |
2024-06-14 |
再生生物股份有限公司 |
用于重组aav生产的组合物和方法
|
|
WO2023060269A1
(en)
|
2021-10-07 |
2023-04-13 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for targeted delivery
|
|
WO2023060272A2
(en)
|
2021-10-07 |
2023-04-13 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns tropic delivery
|
|
US20230151372A1
(en)
*
|
2021-10-07 |
2023-05-18 |
Academia Sinica |
Composition and Method of Treatment for Heart Protection and Regeneration
|
|
US20250042958A1
(en)
|
2021-10-08 |
2025-02-06 |
Sola Biosciences Llc |
Compositions and methods for the treatment of proteopathies
|
|
CA3234720A1
(en)
|
2021-10-08 |
2023-04-13 |
Sola Biosciences Llc |
Compositions and methods for the treatment of p53-mediated cancers
|
|
MX2024004217A
(es)
|
2021-10-08 |
2024-06-26 |
Dyno Therapeutics Inc |
Variantes de cápside y métodos de uso de estas.
|
|
TW202333776A
(zh)
|
2021-10-12 |
2023-09-01 |
美商阿斯帕醫療公司 |
用於治療腦白質失養症的方法及組合物
|
|
CN118525089A
(zh)
|
2021-10-20 |
2024-08-20 |
罗切斯特大学 |
年龄相关的白质损失的再生治疗
|
|
WO2023077092A1
(en)
|
2021-10-28 |
2023-05-04 |
Regenxbio Inc. |
Engineered nucleic acid regulatory elements and methods and uses thereof
|
|
US20230270818A1
(en)
|
2021-11-02 |
2023-08-31 |
University Of Rochester |
Tcf7l2 mediated remyelination in the brain
|
|
WO2023081648A1
(en)
|
2021-11-02 |
2023-05-11 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
WO2023087019A2
(en)
|
2021-11-15 |
2023-05-19 |
The Trustees Of The University Of Pennsylvania |
Compositions for drg-specific reduction of transgene expression
|
|
US20250011372A1
(en)
|
2021-11-17 |
2025-01-09 |
Voyager Thrapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
EP4433490A2
(en)
|
2021-11-17 |
2024-09-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
US20250034559A1
(en)
|
2021-11-17 |
2025-01-30 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
JP2024543918A
(ja)
|
2021-11-29 |
2024-11-26 |
上海瑞宏迪医薬有限公司 |
Ａａｄｃ、ｇｄｎｆポリヌクレオチド及びそのパーキンソン病を治療するための使用
|
|
US20240408157A1
(en)
|
2021-12-02 |
2024-12-12 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of fabry disease
|
|
WO2023114816A1
(en)
|
2021-12-14 |
2023-06-22 |
Neurogene, Inc. |
Recombinant optimized galc constructs and methods for treating galc-associated disorders
|
|
WO2023114897A2
(en)
*
|
2021-12-15 |
2023-06-22 |
Homology Medicines, Inc. |
Methods and compositions for the production of adeno-associated virus
|
|
TW202340467A
(zh)
|
2022-01-10 |
2023-10-16 |
賓州大學委員會 |
有用於治療c9orf72介導之病症之組成物及方法
|
|
EP4463135A2
(en)
|
2022-01-10 |
2024-11-20 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
TW202338086A
(zh)
|
2022-01-10 |
2023-10-01 |
賓州大學委員會 |
有用於治療異染性白質失養症之組成物
|
|
CA3248878A1
(en)
|
2022-01-17 |
2023-07-20 |
Dinaqor Ag |
GENE THERAPY COMPOSITION AND TREATMENT OF DYSTROPHIN-RELATED CARDIOMYOPATHY
|
|
EP4215614A1
(en)
|
2022-01-24 |
2023-07-26 |
Dynacure |
Combination therapy for dystrophin-related diseases
|
|
WO2023147374A2
(en)
|
2022-01-25 |
2023-08-03 |
Voyager Therapeutics, Inc. |
Baculovirus expression system
|
|
WO2023147304A1
(en)
|
2022-01-25 |
2023-08-03 |
The Trustees Of The University Of Pennsylvania |
Aav capsids for improved heart transduction and detargeting of liver
|
|
GB202201242D0
(en)
|
2022-01-31 |
2022-03-16 |
Univ Edinburgh |
Recombinant optimized mecp2 cassettes and methods for treating rett syndrome and related disorders
|
|
US20250144235A1
(en)
|
2022-02-02 |
2025-05-08 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
EP4473011A1
(en)
|
2022-02-02 |
2024-12-11 |
Akouos, Inc. |
Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms
|
|
US20250161485A1
(en)
|
2022-02-08 |
2025-05-22 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
JP2025508720A
(ja)
|
2022-02-17 |
2025-04-10 |
サナ バイオテクノロジー，インコーポレイテッド |
遺伝子操作されたｃｄ４７タンパク質及びその使用関連出願の相互参照
|
|
CA3244192A1
(en)
|
2022-02-21 |
2025-01-22 |
Shanghai Regenelead Therapies Co Ltd |
VEGF-BINDING MOLECULE AND ITS PHARMACEUTICAL USE
|
|
WO2023164545A1
(en)
|
2022-02-23 |
2023-08-31 |
Massachusetts Institute Of Technology |
Methods for upregulating shank3 expression
|
|
US20250101382A1
(en)
|
2022-03-11 |
2025-03-27 |
Sana Biotechnology, Inc. |
Genetically modified cells and compositions and uses thereof
|
|
TW202346590A
(zh)
|
2022-03-13 |
2023-12-01 |
美商銳進科斯生物股份有限公司 |
經修飾之肌肉特異性啟動子
|
|
EP4499154A1
(en)
|
2022-03-25 |
2025-02-05 |
REGENXBIO Inc. |
Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy
|
|
WO2023187728A1
(en)
|
2022-04-01 |
2023-10-05 |
Takeda Pharmaceutical Company Limited |
Gene therapy for diseases with cns manifestations
|
|
TW202345913A
(zh)
|
2022-04-06 |
2023-12-01 |
美商銳進科斯生物股份有限公司 |
用於脈絡膜上投與之調配物諸如凝膠調配物
|
|
CN119317645A
(zh)
|
2022-04-06 |
2025-01-14 |
宾夕法尼亚州大学信托人 |
用于治疗her2阳性转移性乳腺癌及其他癌症的组合物和方法
|
|
US20250250326A1
(en)
|
2022-04-06 |
2025-08-07 |
The Trustees Of The University Of Pennsylvania |
Passive immunization with anti-aav neutralizing antibodies to prevent off-target transduction of intrathecally delivered aav vectors
|
|
AU2023250660A1
(en)
|
2022-04-06 |
2024-10-24 |
Regenxbio Inc. |
Pharmaceutical composition comprising a recombinant adenoassociated virus vector with an expression cassette encoding a transgene for suprachoroidal administration
|
|
TW202404651A
(zh)
|
2022-04-06 |
2024-02-01 |
美商銳進科斯生物股份有限公司 |
用於脈絡膜上投與之調配物諸如形成聚集體之調配物
|
|
TW202404993A
(zh)
|
2022-04-11 |
2024-02-01 |
美商特納亞治療股份有限公司 |
具經工程化蛋白殼之腺相關病毒
|
|
WO2023198652A1
(en)
|
2022-04-11 |
2023-10-19 |
Centre National De La Recherche Scientifique |
Chemically-modified adeno-associated viruses
|
|
WO2023201308A1
(en)
|
2022-04-14 |
2023-10-19 |
Regenxbio Inc. |
Gene therapy for treating an ocular disease
|
|
WO2023201277A1
(en)
|
2022-04-14 |
2023-10-19 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns tropic delivery
|
|
WO2023205610A2
(en)
|
2022-04-18 |
2023-10-26 |
Regenxbio Inc. |
Hybrid aav capsids
|
|
GB202206336D0
(en)
|
2022-04-29 |
2022-06-15 |
Univ Edinburgh |
Recombinant therapeutic FMR1 constructs and methods of treating fragile X syndrome and related disorders
|
|
EP4518972A2
(en)
|
2022-05-03 |
2025-03-12 |
RegenxBio Inc. |
Vectorized anti-complement antibodies and complement agents and administration thereof
|
|
TW202417633A
(zh)
|
2022-05-03 |
2024-05-01 |
美商銳進科斯生物股份有限公司 |
用於眼適應症之載體化抗TNF-α抑制劑
|
|
CA3255627A1
(en)
|
2022-05-06 |
2023-11-09 |
Novartis Ag |
NEW VP2 FUSION POLYPEPTIDES OF RECOMBINANT AAV
|
|
US20250295809A1
(en)
|
2022-05-13 |
2025-09-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
AU2023276729A1
(en)
*
|
2022-05-24 |
2024-12-12 |
Kate Therapeutics, Inc. |
Compositions for treating xlmtm
|
|
KR20250025387A
(ko)
|
2022-06-02 |
2025-02-21 |
보이저 테라퓨틱스, 인크. |
Aav 캡시드 변이체 및 이의 용도
|
|
WO2023240158A2
(en)
*
|
2022-06-07 |
2023-12-14 |
Oregon Health & Science University |
Mutant adeno-associated virus (aav) capsids
|
|
WO2023239627A2
(en)
|
2022-06-08 |
2023-12-14 |
Regenxbio Inc. |
Methods for recombinant aav production
|
|
WO2023240236A1
(en)
|
2022-06-10 |
2023-12-14 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of spinal muscular atrophy related disorders
|
|
CN119731321A
(zh)
|
2022-06-24 |
2025-03-28 |
图恩疗法股份有限公司 |
通过靶向基因阻遏减少低密度脂蛋白的组合物、系统和方法
|
|
WO2024003687A1
(en)
|
2022-06-28 |
2024-01-04 |
Pfizer Inc. |
Nucleic acids encoding acid alpha-glucosidase (gaa) and vectors for gene therapy
|
|
CA3259902A1
(en)
|
2022-06-28 |
2024-01-04 |
Voyager Therapeutics Inc |
AAV Capsid Variants and Their Uses
|
|
JP2025525439A
(ja)
|
2022-06-30 |
2025-08-05 |
インダプタ セラピューティクス インコーポレイテッド |
操作されたナチュラルキラー（ｎｋ）細胞と抗体療法との組み合わせおよび関連する方法
|
|
AR129843A1
(es)
|
2022-07-06 |
2024-10-02 |
Voyager Therapeutics Inc |
Variantes de la cápside de aav y usos de estas
|
|
EP4558149A1
(en)
|
2022-07-21 |
2025-05-28 |
Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating chronic pain disorders
|
|
WO2024026377A1
(en)
|
2022-07-27 |
2024-02-01 |
Sana Biotechnology, Inc. |
Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
|
|
JP2025528068A
(ja)
|
2022-08-03 |
2025-08-26 |
ボイジャー セラピューティクス インコーポレイテッド |
血液脳関門を通過させるための組成物及び方法
|
|
WO2024038365A1
(en)
|
2022-08-16 |
2024-02-22 |
Pfizer Inc. |
Methods for purification of aav vectors by anion exchange chromatography
|
|
WO2024044725A2
(en)
|
2022-08-24 |
2024-02-29 |
Regenxbio Inc. |
Recombinant adeno-associated viruses and uses thereof
|
|
WO2024042485A1
(en)
|
2022-08-25 |
2024-02-29 |
Takeda Pharmaceutical Company Limited |
Composition for use in the treatment of fabry disease
|
|
WO2024054983A1
(en)
|
2022-09-08 |
2024-03-14 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
UY40443A
(es)
|
2022-09-22 |
2024-02-15 |
Biomarin Pharm Inc |
Tratamiento de la miocardiopatía con vectores de genoterapia con aav
|
|
TW202421788A
(zh)
|
2022-09-22 |
2024-06-01 |
美商拜奧馬林製藥公司 |
用ａａｖ基因療法載體治療致心律不整性心肌病
|
|
WO2024073669A1
(en)
|
2022-09-30 |
2024-04-04 |
Regenxbio Inc. |
Treatment of ocular diseases with recombinant viral vectors encoding anti-vegf fab
|
|
US20250108130A1
(en)
*
|
2022-10-04 |
2025-04-03 |
Siren Biotechnology, Inc. |
Modified cpg dinucleotides for recombinant viral vector production
|
|
WO2024081746A2
(en)
|
2022-10-11 |
2024-04-18 |
Regenxbio Inc. |
Engineered nucleic acid regulatory elements and methods and uses thereof
|
|
WO2024105638A1
(en)
|
2022-11-18 |
2024-05-23 |
Jcr Pharmaceuticals Co., Ltd. |
Recombinant aav vectors and methods for treatment of hunter syndrome
|
|
CN121127599A
(zh)
|
2022-12-17 |
2025-12-12 |
宾夕法尼亚州大学信托人 |
具有心肌和骨骼肌特异性靶向基序的重组aav突变载体及含有其的组合物
|
|
WO2024130070A2
(en)
|
2022-12-17 |
2024-06-20 |
The Trustees Of The University Of Pennsylvania |
Recombinant aav capsids with cardiac- and skeletal muscle- specific targeting motifs and uses thereof
|
|
IT202200026595A1
(it)
|
2022-12-22 |
2024-06-22 |
Fond Telethon Ets |
Nuovi inibitori di regolatori epigenetici
|
|
CN120752339A
(zh)
|
2023-01-06 |
2025-10-03 |
国家医疗保健研究所 |
静脉内施用用于治疗疼痛的反义寡核苷酸
|
|
WO2024151541A1
(en)
|
2023-01-09 |
2024-07-18 |
Sana Biotechnology, Inc. |
Type-1 diabetes autoimmune mouse
|
|
EP4649160A1
(en)
|
2023-01-12 |
2025-11-19 |
Nantes Université |
Chemically-modified adeno-associated virus
|
|
EP4658294A2
(en)
|
2023-02-02 |
2025-12-10 |
University of Rochester |
Competitive replacement of glial cells
|
|
WO2024163979A2
(en)
*
|
2023-02-02 |
2024-08-08 |
Codexis, Inc. |
Engineered aav polypeptides
|
|
WO2024163012A1
(en)
|
2023-02-02 |
2024-08-08 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
TW202449165A
(zh)
|
2023-02-17 |
2024-12-16 |
美商渤健麻塞諸塞州股份有限公司 |
用於遞送有效載荷之含ｒｇｄ之肽
|
|
WO2024192281A2
(en)
|
2023-03-15 |
2024-09-19 |
Regenxbio Inc. |
Exon skipping gene therapy constructs, vectors and uses thereof
|
|
KR20250158036A
(ko)
|
2023-03-17 |
2025-11-05 |
유니버시티 오브 로체스터 |
리보자임-매개 rna 조립 및 발현
|
|
AU2024245299A1
(en)
*
|
2023-03-25 |
2025-09-25 |
Duke University |
Compositions comprising kidney-tropic aavs and methods of use thereof
|
|
WO2024211780A1
(en)
|
2023-04-07 |
2024-10-10 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
|
WO2024215653A1
(en)
|
2023-04-10 |
2024-10-17 |
Tenaya Therapeutics, Inc. |
Guide rnas, vectors, and virions for targeting mutations in the pln gene
|
|
WO2024215655A1
(en)
|
2023-04-10 |
2024-10-17 |
Tenaya Therapeutics, Inc. |
Cardioprotective bag3 therapies
|
|
WO2024216244A2
(en)
|
2023-04-13 |
2024-10-17 |
Regenxbio Inc. |
Targeting aav capsids, methods of manufacturing and using same
|
|
WO2024220389A2
(en)
*
|
2023-04-17 |
2024-10-24 |
University Of Massachusetts |
Aav2 variants and uses thereof
|
|
WO2024220463A2
(en)
*
|
2023-04-17 |
2024-10-24 |
University Of Massachusetts |
Aav5 capsid with non-canonical amino acid incorporation and uses thereof
|
|
WO2024218192A1
(en)
|
2023-04-18 |
2024-10-24 |
Uniqure Biopharma B.V. |
Novel neurotropic adeno-associated virus capsids with detargeting of peripheral organs
|
|
WO2024218190A1
(en)
|
2023-04-18 |
2024-10-24 |
Uniqure Biopharma B.V. |
Generation of adeno-associated virus capsid libraries for insect cells
|
|
WO2024226761A2
(en)
|
2023-04-26 |
2024-10-31 |
Voyager Therapeutics, Inc. |
Compositions and methods for treating amyotrophic lateral sclerosis
|
|
WO2024226790A1
(en)
|
2023-04-26 |
2024-10-31 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
AU2024264889A1
(en)
|
2023-05-03 |
2025-11-13 |
Sana Biotechnology, Inc. |
Methods of dosing and administration of engineered islet cells
|
|
WO2024229309A2
(en)
|
2023-05-03 |
2024-11-07 |
Manifold Biotechnologies, Inc. |
Methodsand compositions for high-throughput protein delivery, screening, and detection
|
|
WO2024229125A2
(en)
|
2023-05-03 |
2024-11-07 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to frataxin deficiency
|
|
WO2024229167A1
(en)
|
2023-05-03 |
2024-11-07 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to syntaxin-binding protein 1 deficiency
|
|
WO2024229163A1
(en)
|
2023-05-03 |
2024-11-07 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to cdkl5 deficiency
|
|
WO2024229389A1
(en)
|
2023-05-03 |
2024-11-07 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
TW202444917A
(zh)
|
2023-05-04 |
2024-11-16 |
美商航海家醫療公司 |
Ａａｖ衣殼變異體及其用途
|
|
WO2024233422A1
(en)
|
2023-05-05 |
2024-11-14 |
Massachusetts Institute Of Technology |
Shank3 gene therapy approaches
|
|
WO2024233529A2
(en)
|
2023-05-07 |
2024-11-14 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
|
WO2024238853A1
(en)
|
2023-05-16 |
2024-11-21 |
Regenxbio Inc. |
Adeno-associated viruses for ocular delivery of gene therapy
|
|
WO2024238859A1
(en)
|
2023-05-16 |
2024-11-21 |
Regenxbio Inc. |
Vectorized c5 inhibitor agents and administration thereof
|
|
WO2024238867A1
(en)
|
2023-05-16 |
2024-11-21 |
Regenxbio Inc. |
Vectorized anti-complement antibodies and administration thereof
|
|
WO2024243236A2
(en)
|
2023-05-22 |
2024-11-28 |
Sana Biotechnology, Inc. |
Methods of delivery of islet cells and related methods
|
|
WO2024241176A1
(en)
|
2023-05-24 |
2024-11-28 |
Jcr Pharmaceuticals Co., Ltd. |
Recombinant aav vectors and methods for treatment of diseases with central nervous system disorders
|
|
WO2024258961A1
(en)
|
2023-06-12 |
2024-12-19 |
The Trustees Of The University Of Pennsylvania |
Aav gene therapy for mucopolysaccharidosis iiib
|
|
AR133098A1
(es)
|
2023-06-29 |
2025-08-27 |
Univ Pennsylvania |
Aav mutante con motivos dirigidos al sistema nervioso central y composiciones que lo contienen
|
|
WO2025008406A1
(en)
|
2023-07-04 |
2025-01-09 |
Institut National de la Santé et de la Recherche Médicale |
Antisense oligonucleotides and their use for the treatment of cancer
|
|
WO2025017168A1
(en)
|
2023-07-19 |
2025-01-23 |
Genethon |
Novel optimized utrophin micro-genes
|
|
WO2025017169A1
(en)
|
2023-07-20 |
2025-01-23 |
Genethon |
Novel mididystrophins
|
|
WO2025035143A1
(en)
|
2023-08-10 |
2025-02-13 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of spinal muscular atrophy
|
|
WO2025042711A1
(en)
|
2023-08-18 |
2025-02-27 |
Eli Lilly And Company |
Engineered transferrin receptor binding peptides as well as methods of making and using the same
|
|
WO2025072604A1
(en)
|
2023-09-28 |
2025-04-03 |
University Of Rochester |
Rna-editing gene therapy approaches for treating myotonic dystrophy type 1 (dm1)
|
|
WO2025075963A1
(en)
|
2023-10-02 |
2025-04-10 |
Regenxbio Inc. |
Methods and formulations for treating mucopolysaccharidosis ii-associated hearing loss with recombinant human iduronate-2-sulfatase
|
|
WO2025080780A1
(en)
|
2023-10-10 |
2025-04-17 |
University Of Rochester |
Delivery and expression of prime editing crispr systems
|
|
WO2025090427A1
(en)
|
2023-10-23 |
2025-05-01 |
University Of Rochester |
Glial-targeted relief of hyperexcitability in neurodegenerative diseases
|
|
WO2025090962A1
(en)
|
2023-10-25 |
2025-05-01 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
|
WO2025090858A1
(en)
|
2023-10-27 |
2025-05-01 |
Biogen Ma Inc. |
Methods for identifying aav capsid variants with desired characteristics
|
|
TW202535908A
(zh)
|
2023-11-02 |
2025-09-16 |
美商渤健麻塞諸塞州股份有限公司 |
中樞神經系統靶向之ａａｖ衣殼之重定向
|
|
WO2025102034A1
(en)
|
2023-11-10 |
2025-05-15 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for barth syndrome
|
|
WO2025106374A1
(en)
|
2023-11-13 |
2025-05-22 |
Juno Therapeutics, Inc. |
Aav production method
|
|
WO2025106661A1
(en)
|
2023-11-14 |
2025-05-22 |
The Trustees Of The University Of Pennsylvania |
Compositions with cardiac and skeletal musclespecific targeting motifs and uses thereof
|
|
WO2025108407A2
(en)
|
2023-11-23 |
2025-05-30 |
Neuexcell Therapeutics (Suzhou) Co., Ltd. |
Gene therapy compositions and methods for treating glioma
|
|
WO2025113676A1
(en)
|
2023-11-29 |
2025-06-05 |
Neuexcell Therapeutics (Suzhou) Co., Ltd. |
Compositions and methods for treating stroke in primates
|
|
WO2025122543A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to syntaxin-binding protein 1 deficiency
|
|
WO2025122532A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to ataxin-2
|
|
WO2025122548A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to cdkl5 deficiency
|
|
WO2025122536A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase
|
|
WO2025129157A1
(en)
|
2023-12-15 |
2025-06-19 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treatment of canavan disease
|
|
WO2025137219A1
(en)
|
2023-12-21 |
2025-06-26 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase
|
|
WO2025147436A1
(en)
|
2024-01-03 |
2025-07-10 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
WO2025171001A1
(en)
|
2024-02-06 |
2025-08-14 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for improved production of aav viral vectors
|
|
WO2025188625A1
(en)
|
2024-03-03 |
2025-09-12 |
Passage Bio, Inc. |
Recombinant adeno-associated virus for treatment of neurodegenerative disorders
|
|
US20250276095A1
(en)
|
2024-03-04 |
2025-09-04 |
Kate Therapeutics, Inc. |
Adeno-associated virus compositions for the treatment of duchenne muscular dystrophy
|
|
WO2025207932A1
(en)
|
2024-03-27 |
2025-10-02 |
Biogen Ma Inc. |
Aav capsids comprising anti-transferrin antibody domains
|
|
WO2025207948A1
(en)
|
2024-03-27 |
2025-10-02 |
Biogen Ma Inc. |
Aav capsids for targeting human transferrin receptor
|
|
WO2025217214A2
(en)
|
2024-04-08 |
2025-10-16 |
Regenxbio Inc. |
Recombinant adeno-associated viruses and uses thereof
|
|
WO2025217230A1
(en)
|
2024-04-08 |
2025-10-16 |
Regenxbio Inc. |
Vectorized anti-complement antibodies and complement agents and administration thereof
|
|
WO2025226842A1
(en)
|
2024-04-24 |
2025-10-30 |
Kate Therapeutics, Inc. |
Expression control by drg-expressed mirnas
|
|
WO2025226841A1
(en)
|
2024-04-24 |
2025-10-30 |
Kate Therapeutics, Inc. |
Gene therapy approach for treating disorders associated with tnnt2
|
|
WO2025235734A2
(en)
|
2024-05-09 |
2025-11-13 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
WO2025237990A1
(en)
|
2024-05-14 |
2025-11-20 |
Institut National de la Santé et de la Recherche Médicale |
Antisense oligonucleotides and their use for the treatment of pulmonary fibrosis
|
|
GB202407038D0
(en)
|
2024-05-17 |
2024-07-03 |
Axovia Therapeutics Ltd |
Novel Gene Therapy
|
|
WO2025242657A1
(en)
|
2024-05-21 |
2025-11-27 |
Shape Biopharmaceuticals Ag |
Lipopeptide building blocks and aggregates
|
|
WO2025250457A1
(en)
|
2024-05-28 |
2025-12-04 |
University Of Rochester |
Enhanced brain transduction by gene therapeutics
|